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ABSTRACT 
 
Megan Garcia Meyer: The protease/antiprotease balance determines influenza 
susceptibility and can be modified by oxidants and antioxidants 
(Under the direction of Ilona Jaspers) 
 
 The respiratory epithelium functions as a central orchestrator to initiate and 
organize responses to inhaled stimuli. Proteases and antiproteases are secreted from the 
respiratory epithelium and are involved in respiratory homeostasis. Modifications to the 
protease/antiprotease balance can lead to the development of lung diseases such as 
emphysema or chronic obstructive pulmonary disease. Furthermore, altered 
protease/antiprotease balance, in favor for increased protease activity, is associated with 
increased susceptibility to respiratory viral infections such as influenza virus. We 
demonstrated that inhaled oxidants, such as cigarette smoke, alters intracellular regulation 
and extracellular modifications of a key respiratory antiprotease, secretory leukocyte 
protease inhibitor (SLPI). Additionally, we established that SLPI is a novel anti-influenza 
biomarker that restricts influenza infection in vivo and in vitro. Furthermore, we 
investigated the effect of nutritional antioxidants, such as sulforaphane (SFN), on SLPI 
expression and found that SFN induced SLPI expression and secretion using in vivo and 
in vitro models. Finally, we detailed that smokers have increased secretions of an 
influenza-activating protease, transmembrane protease serine 2 (TMPRSS2) and that SFN 
supplementation reduced TMPRSS2 secretion, which protected against influenza 
infection in vitro. Taken together, these studies establish the integral role of the 
respiratory protease/antiprotease balance in the context of an influenza infection and after 
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oxidant/antioxidant exposure. Further, these findings have broad implications for other 
inhaled oxidants, such as wood smoke and ozone, and offer the use of SFN as possible 
nutritional therapeutic to boost respiratory mucosal responses and/or protect against 
influenza infection. 
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CHAPTER 1  
Introduction  
 
 Nearly 40 different types of cells have been identified in the respiratory tract, 
including neutrophils, dendritic cells, macrophages,  natural killer (NK) cells, B cells, and 
T cells (1). Due to this diverse population of cells, a central “orchestrator” is necessary 
for coordinating an appropriate immune response to inhaled stimuli. The respiratory 
epithelium is one of the first sites within the respiratory tract to be exposed to inhaled 
stimuli and functions as a focal “orchestrator” to organize and initiate appropriate 
responses in three distinct ways (Figure 1-1). First, the respiratory epithelium forms a 
physical barrier through tightly regulated cell-cell interactions. These interactions 
promote basic biologic functions, protect against invading pathogens, and establish 
mechanical strength. Second, epithelial cells express receptors and ligands that coordinate 
cellular responses and activate immune cells. These processes are important for detecting 
foreign stimuli, communicating among different cells, and guiding immune responses. 
Third, respiratory epithelial cells secrete soluble factors such as cytokines, chemokines, 
and host defense mediators such as mucins, lactoferrin, defensins, and 
proteases/antiproteases. These secreted, soluble factors are crucial for the overall host 
defense response, as well as orchestration of immune cell recruitment and activation. In 
the context of antimicrobial host defense responses, epithelial function can be modulated 
by include intrinsic factors, such as age, and extrinsic factors, such as inhaled oxidants 
and supplementation with nutritional antioxidants. As such, this dissertation will examine 
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the role of secreted soluble factors, such as the protease/antiprotease balance, in response 
to oxidants, antioxidants, and viral infection. These findings will elucidate the impact of 
this balance in the context of a respiratory viral infection and further highlight how 
respiratory epithelial cells are master regulators of respiratory function. 
1.1 Respiratory epithelium serves as a central “orchestrator” to initiate and 
coordinate respiratory responses 
1.1.1 Barrier and mechanical functions of the respiratory epithelium  
 The respiratory epithelium is comprised of basal, secretory, and ciliated cells that 
vary in number and density throughout the respiratory tract (2, 3). Playing an integral role 
in the respiratory structure, basal cells firmly attach to the basement membrane (4). 
Secretory cells are comprised of goblet cells, which secrete mucus, a gel-like network 
that is important for trapping foreign objects (5). Ciliated columnar cells are the most 
numerous cell type of the respiratory tract that arise from either basal or secretory cells 
(3). These cells express mechanical organelles called cilia, which are extracellular 
machinery proteins that clear foreign substances trapped in the mucus matrix. 
 The respiratory epithelium maintains its well-defined structure through the use of 
tight junctions (TJ), desmosomes, adherens junctions (AJ), and gap junctions (GJ) (6). 
These proteins form an impervious barrier and allow for diffusion of electrolytes and 
other molecules involved in cell signaling and physiology. TJ, located on the peaks of 
neighboring cells, are integral for maintaining epithelial integrity and are also used for 
communication between adjacent cells (7). TJ proteins include claudins, occludins, 
zonaoccludens, catenins, and F-actin (8).  Mechanical strength is achieved in the 
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respiratory epithelium through the connective network and strength of desmosomes (9). 
AJ function similarly to desmosomes, serving as an adhesive between adjacent cells. 
Located below TJ, AJ serve as critical epithelial linkers to cytoskeleton actin filaments 
(10). Lastly, GJ form clusters of channels that link neighboring cells and allow for ion, 
secondary messenger, and metabolite transport (11). 
 Beyond barrier protection, the respiratory epithelium is equipped with mechanical 
strategies to protect against foreign inhaled insults. The respiratory epithelium is coated 
with mucus, a thin viscoelastic gel that allows for hydration of the epithelium. Mucus is 
comprised of proteins called mucins that form the structural network of the mucus lining 
(12, 13).  Mucins are large glycoproteins that are encoded by MUC genes and provide the 
viscoelastic properties of mucus. To date, over 10 mucin genes have been detected, with 
MUC5AC and MUC5B being the most prevalent mucins found in human sputum 
secretions (14).  Mucus is not only important for hydration but also is a vital component 
for the mucocillilary escalator, a mechanical process that traps and clears foreign 
particles. The escalator function is achieved by ciliary movement and beating, which 
pushes the mucus and trapped foreign particles out of the respiratory tract. However, 
elevated MUC levels can be detrimental for respiratory health since increased MUC5AC 
and MUC5B are increased in chronic obstructive pulmonary disease (COPD) and asthma 
patients (15, 16). In sum, physical and mechanical properties of the respiratory 
epithelium promote respiratory homeostasis and protect against injurious stimuli.  
1.1.2 Receptor-mediated interactions of the respiratory epithelium 
 The respiratory epithelium functions beyond barrier and mechanical function by 
detecting foreign stimuli as well as interacting with neighboring cells and respiratory 
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immune cells. One mechanism of detection involves pattern recognition receptors 
(PRRs), which are receptors that recognize conserved microbial motifs, termed pathogen 
associated molecular patterns (PAMPs), and endogenous ligands produced from stressed 
cells, termed damage associated molecular patterns (DAMPs) (17). Respiratory epithelial 
cells possess a wide variety PRRs such as toll-like receptors (TLRs), nod-like receptors 
(NLRs), C-type lectin receptors (CLRs), and retinoic acid-inducible gene I-like receptors 
(RLRs). CLRs and some TLRs serve as extracellular sensors, while NLRs, RLRs, and 
some TLRs act as intracellular sensors (18-20). Furthermore, epithelial cells express 
various receptors such as integrins and adhesion molecules that bind to inhaled stimuli, 
such as respiratory viruses, and allow for infection (21, 22). Once foreign stimuli are 
detected, respiratory epithelial cells communicate with neighboring cells and immune 
cells through extracellular receptors and ligands (23). These physical signals are 
important for mounting and controlling immune responses.  
 Once injurious stimuli have been detected, respiratory epithelial cells produce 
soluble factors such as cytokines and chemokines. Cytokines and chemokines attract 
immune cells, such as  NK cells, B cells, and T cells, that are important for cellular 
immunity (24). Cytokine and chemokine production are induced by transcription factors 
such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and 
interferon regulatory factor (IRF). Additionally, type I interferons (IFN) serve as an 
expansive signal to warn neighboring respiratory epithelial cells as well as resident 
immune cells. This broad spectrum IFN signal is further amplified by intracellular Janus 
kinase (JAK) and Signal Transducer and Activator of Transcription (STAT) signaling 
(25). JAK/STAT activation induces host defense genes, cytokines, and chemokines.  In 
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summary, the respiratory epithelium serves an important “orchestrator” to promote 
barrier and mechanical function, moderate receptor-mediated interactions, and produce 
soluble factors that contribute to respiratory host defense.    
1.2 Epithelial cell-derived secreted host defense mediators exhibit novel 
antimicrobial effects  
1.2.1 Lysozyme and lactoferrin: the most abundant host defense mediators found in the 
respiratory tract   
 In addition to the production and secretion of cytokines and chemokines, 
epithelial cells secrete host defense mediators that possess broad antimicrobial properties 
and are imperative for the early, innate responses to infection. Two of the most abundant 
host defense mediator found in respiratory nasal secretions or sputum samples are 
lysozyme and lactoferrin (26, 27). Lysozyme is a 14 kilodalton (kDa) enzyme that 
cleaves bacterial cell wall components, such as peptidogycan, which results in bacterial 
cell lysis. Lysozyme possesses antimicrobial activity against many Gram-positive 
microbes, but is less effective against Gram-negative bacteria (28). When challenged 
with group B streptococci, transgenic mice that over-expressed lysozyme in the lung 
cleared the bacterial infection and had enhanced rates of survival compared to wild type 
mice (29). Lysozyme is induced by enveloped viruses; however, viruses such as influenza 
A virus (IAV) antagonize lysozyme function by inhibiting lysozyme release from cells 
(30, 31).  
 Lactoferrin is an 80kDa iron-binding protein secreted from epithelial cells and 
innate immune cells such as neutrophils. Lactoferrin exhibits antimicrobial activity by 
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sequestering iron, a required nutrient for microbial growth (32). Additionally, lactoferrin 
binds to lipopolysaccharide (LPS), a bacterial cell wall component, which results in 
bacterial permeabilization (33). Lactoferrin also prevents viral entry either by blocking 
host extracellular receptors or by directly binding to the viruses to prevent entry (34). 
Moreover, lactoferrin alters immune responses. Shin et al. reported that mice treated with 
lactoferrin before intranasal infection with IAV had an attenuated rate of pro-
inflammatory cytokines such as interleukin 6 (IL-6), leukocyte infiltrate, and lung 
destruction compared to control animals (35). These findings indicate that while 
lysozyme and lactoferrin exhibit anti-viral properties, lactoferrin may possess greater 
anti-IAV properties than lysozyme. 
1.2.2 Lung lipid mediators: surfactant proteins 
 Lung surfactant proteins (SP) are an additional class of secreted respiratory 
proteins that are comprised of four different subtypes: SP-A, SP-B, SP-C, and SP-D. SP 
can form multimers to increase accessibility and affinity to immune cells and pathogens, 
similar to antibody function (36). SP-B and SP-C are hydrophobic and regulate alveolar 
surface tension, while SP-A and SP-D are hydrophilic and mainly contribute to epithelial 
host defense responses (37). SP-A and SP-D range in size from 26-43 kDa and possess 
many carbohydrate-rich domains, which are important for agglutination and 
neutralization of bacteria and viruses (38-40). Oxidant exposure, such as diesel exhaust 
particles, decreases SP-A and SP-D levels and correlates with increased susceptibility to 
IAV infection (41). Furthermore, LeVine et al. reported that SP-D knockout mice had 
decreased viral clearance and increased levels of pro-inflammatory cytokines when 
infected with IAV (42). Additionally, SP-D induces innate cell recruitment and stimulates 
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phagocytosis and clearance of apoptotic cells (43, 44).  Of note, genetic alterations to the 
SP-A gene is associated with increased risk for mechanical ventilation and acute 
respiratory failure during IAV pandemics (45). Together, these studies illuminate the 
potent respiratory anti-IAV effects of SP-A and SP-D.  
1.2.3 Respiratory cationic peptides: cathelicidins and defensins 
 Cathelicidins are cationic peptides secreted from neutrophil and macrophage 
granules as well as epithelial cells. The only cathelicidin found in humans is the 18kDa 
protein human cationic antimicrobial protein 18 (hCAP18) (46). hCAP18 binds and 
neutralizes bacterial LPS (47). Additionally, hCAP18 can be cleaved, resulting in the 
generation of LL-37, a 4.5kDa antimicrobial peptide that contains two leucine resides on 
its N-terminal domain. LL-37 stimulates various intracellular signaling cascades, such as 
the NF-κB and mitogen-activated protein kinase (MAPK) pathways, involved in 
inflammation and proliferation (48-50).   
 Similar to hCAP18, LL-37 disrupts microbial membranes and stimulates immune 
responses by recruiting both innate and adaptive immune cells, such as monocytes, 
neutrophils, and T cells, to sites of infection (51). Furthermore, LL-37 is protective 
against respiratory viruses, such as IAV, by disrupting viral membrane integrity and viral 
attachment to target cells (52, 53). In addition to direct anti-viral activities, LL-37 exerts 
immunomodulatory effects in response to influenza infection. IAV infected mice treated 
with LL-37 had decreased viral replication and dampened pro-inflammatory cytokines 
such as interleukin-1β (IL-1 β) and macrophage inflammatory protein-α (54).  Moreover, 
LL-37  alters innate immune cell function, as seen in LL-37 treated human neutrophils 
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infected with IAV infection had increased H2O2 release and neutrophil extracellular trap 
formation (55). 
 Defensins (α, β, θ) are an additional family of highly cationic peptides that exert 
both antibacterial and anti-viral properties (56, 57). α-defensins are produced by 
leukocytes, β-defensins (HBDs) are primarily produced by epithelial cells and θ-
defensins are found in non-human primates (58). While over eight HBDs have been 
identified, only HBD1-3 have been isolated from human tissue. HBD1 is constitutively 
expressed and is primarily expressed in the epithelium of urinary and respiratory tracts 
(59, 60). HBD2 and HBD3 are expressed in the skin and mouth as well as the 
gastrointestinal and respiratory tracts (61). HBD2 and HBD3 are induced in response to 
inflammatory stimuli in an NF-κB-dependent manner (62, 63).   
 During viral infection, HBD2 and 3 directly bind and neutralize viruses. Sun et al. 
demonstrated that HBD2 and 3 inhibited early products of viral reverse transcription after 
human immunodeficiency virus (HIV) infection, indicating that HBDs inhibit HIV 
replication (64). Similar anti-viral effects specific to HBDs were seen in the context of 
respiratory viral infection.  During respiratory syncytial virus (RSV) infection, HBD2 
destabilizes the viral envelope and prevents RSV entry into target cells (65).  In vitro 
infection of primary airway epithelial cultures with human rhinovirus (HRV) induces 
HBD2 mRNA that is dependent on intracellular dsRNA levels (66). Furthermore, HBD2 
expression and secretion is induced after human in vivo HRV infection (66).  In cell 
culture and mouse models of IAV infection, β-defensins confer protection by blocking 
influenza entry and replication (67-70). Due to their cationic nature, cathelicidins and 
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defensins protect against viral infection by disrupting viral membrane permeability, 
blocking viral entry, and modulating cellular immune responses to viral infection.  
1.2.4 Proteases and antiproteases of the lung: a delicate enzymatic balance  
 In addition to antimicrobial peptides, proteases and antiproteases are key 
components of respiratory host defense. In the healthy lung, proteases maintain tissue 
homeostasis and their activities are regulated by antiproteases. Elevated net protease 
activity is associated with lung destruction and the development of chronic lung diseases 
such as emphysema and COPD (71, 72). Lung destruction is induced by proteolytic 
degradation of extracellular matrix (ECM) components, including collagens, laminins, 
and elastin, with type I collagen serving as the major target (73). Cysteine proteases, 
matrix metalloproteinases (MMPs), and serine proteases are prevalent proteases found in 
the lung, with serine proteases serving as the most predominant class. Moreover, each 
family has unique target substrates, cellular sources, and active sites (Table 1-1).  
 Cysteine proteases are synthesized as pro-enzymes, require cleavage for 
activation, and contain conserved cysteine and histidine residues, with the cysteine 
serving as a nucleophile for target motifs.  Cathepsin B, K, L, and S are highly abundant 
in the lung, and cathepsin K, mainly produced in bronchial epithelial cells, is one of the 
most potent matrix-degrading proteases identified to date (74). Cathepsins cleave elastin, 
laminin, and collagen as well as antiproteases such as secretory leukocyte protease 
inhibitor (SLPI) and are important for major histocompatibility complex II formation and 
antigen presentation (75-77). Cathepsins have been linked to respiratory virus infection 
since cathepsin L cleaves and activates the spike protein of severe acute respiratory 
10 
 
syndrome coronavirus (SARS-CoV), and cathepsin B is induced during IAV infection in 
mice (78, 79).  
  MMPs are a family of metal endopeptidases that target ECM components. 
Secreted by immune cells and epithelial cells, MMPs possess a common prodomain and 
catalytic domain. Because MMPs are synthesized as inactive zymogens, the signal 
domain must be cleaved for MMPs activity. The catalytic domain contains a conserved 
zinc binding site that confers protease activity. MMP1, 2, 3, 7, 8, 9, 12, and 13 are the 
main MMPs found in the respiratory tract and are induced by growth factors, reactive 
oxygen species, and pro-inflammatory cytokines (80-82). MMP1, 8, and 13 cleave 
collagen, while MMP2 and 9 act as gelatinases and also degrade elastin and type IV 
collagen (83, 84).  
 Additionally, increased MMP activity is associated with inflammation. Baseline 
MMPs levels such as MMP1, 2, 3, 8, and 9 are elevated in smokers and patients with 
COPD (85). Moreover, MMP9 cleaves pro-inflammatory cytokines such as interleukin-8 
(IL-8), resulting in the release of a modified, more potent neutrophil chemotactic 
mediator (86). MMP12 degrades elastin but also inactivates key antiproteases in the lung 
such as SLPI (87). While MMP activity has not been implicated in viral activation, 
MMPs are involved in viral-induced inflammation. In epithelial cell lines and mouse 
models, MMP2 and 9 are induced during IAV infection and contribute to the IAV-
associated lung destruction (88-90). Tacon et al. demonstrated that MMPs levels are 
elevated in vitro and in vivo during HRV infection, which was dependent on NF-κB, 
further illustrating the role of MMPs in virus-induced respiratory inflammation (91).  
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  Serine proteases make up the largest portion of respiratory proteases (92). While 
neutrophil elastase (NE), proteinase 3, and cathepsins G are neutrophil-derived proteases, 
other serine proteases such as type II transmembrane serine proteases (TTSPs) are 
produced and secreted by the respiratory epithelium. TTSPs are a family of proteases that 
contain an N-terminal transmembrane domain, a stem region, and a C-terminal serine 
protease domain that contains the conserved catalytic triad composed of histidine, 
aspartic acid, and serine (93). Protease activity is attained through the nucleophilic serine, 
which attacks the substrate’s carbonyl functional group. This activity generates an acyl 
intermediate, transfers a proton from the positively charged histidine to the substrate, and 
allows for the hydrolysis and cleavage of the substrate (94). TTSPs are synthesized as a 
single chain, inactive pro-enzyme and require cleavage following a basic arginine or 
lysine (95). The catalytic domains are located on the terminal extracellular region to 
permit direct exposure to the extracellular environment.  
 TTSPs are comprised of four subfamilies: the human airway trypsin-like 
protease/differentially expressed in squamous cell carcinoma (HAT)/(DESC) subfamily 
that include HAT, DESC1, and HAT-like 1-5; the hepsin/transmembrane protease serine 
(TMPRSS) subfamily contains hepsin, TMPRSS2-5 and 13, mosaic serine protease large-
form, and enteropeptidase; the corin protease, and the matriptase subfamily that includes 
matriptase 1-3, and polyserase-1 (94). While TTSPs are transmembrane proteases, release 
of the extracellular domains has been reported for several of the TTSPs such as 
matriptase, HAT, and TMPRSS2 (96, 97). Moreover, matriptase, HAT, and TMPRSS2 
are widely expressed in epithelial tissues, including the respiratory tract.  
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 Matriptase cleaves and activates protease-activated receptor 2 (PAR2), hepatocyte 
growth factor, and urokinase, indicating that matriptase plays a role not only in ECM 
degradation but also in epithelial cell differentiation and remodeling (98, 99). In the 
respiratory epithelium, matriptase is expressed on the basolateral side of the epithelial 
cells. Upon activation, matriptase migrates to the apical side of the epithelium, where it 
can be secreted into the lumen of the respiratory tract. Recent studies have revealed that 
intracellular matriptase localizes to the plasma membrane and endosomes, allowing for 
interaction and activation of the IAV virion (100, 101).  Moreover, secreted matriptase 
cleaves hemagglutinin (HA) protein on the IAV virion, including H1, but not H2 or H3, 
which activates the virion and allows for enhanced rates of replication (100, 101).  
   HAT cleaves fibrinogen, activates PAR2, and urokinase (101). In sputum samples 
from patients with chronic airway disorders such as bronchitis or asthma, secreted HAT 
levels are elevated (96). Moreover, Chokki, et al. demonstrated that HAT enhanced 
MUC5AC gene expression, resulting in increased mucus production (102). HAT is 
produced and secreted by ciliated epithelial cells, and is not found in basal or goblet cells 
of the respiratory tract (103).  HAT activates the SARS-CoV viral spike protein necessary 
for host cell entry (104).  Moreover, HAT cleaves the monobasic site of the HA protein 
required for HA activation, enhancing IAV replication (105-107). Cleavage of HA by 
HAT has been shown to occur at the cell surface either during attachment and entry into 
host cells or during budding and shedding of virions from an infected cell (106).  
 TMPRSS2 possesses a wide range of functions specific to epithelial cell biology. 
Donaldson et al. demonstrated that TMPRSS2 reduced epithelial sodium channel activity, 
indicating a role for TMPRSS2 in ion transport (108). TMPRSS2 can be expressed as a 
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full length 70kDa protein, or a variety of smaller, truncated forms, depending on tissue 
site and localization (97, 109). TMPRSS2 mRNA levels are elevated in prostate cancer 
cell lines and nearly two-fifths of prostate cancer patients express duplication of the 
TMPRSS2 gene (110, 111). Increased levels of TMPRSS2 in prostate cancer cells are 
found as a gene fusion product of TMPRSS2 with an E-twenty-six (ETS) transcription 
factor, such as ERG and ETV (112). This fusion event generates a C-terminally truncated 
TMPRSS2 protein attached to an N-terminally truncated ERG/ETV protein, which 
induces migration and invasion in non-tumorigenic epithelial prostate cells (113). The 
TMPRSS2-ERG/ETV gene fusion is regulated by androgen receptor (AR) signaling and 
is associated with a high rate of prostate cancer recurrence and/or severe disease (114-
116).   
 Additionally, TMPRSS2 is implicated in the activation of respiratory viruses. 
Cells expressing TMPRSS2 show enhanced replication of human metapneumovirus as 
well as increased activation and replication of SARS-CoV (117, 118).  Bottcher et al. 
reported that cells stably expressing TMPRSS2 resulted in the monobasic cleavage of 
HA, which elevated IAV replication (105, 107). In recent reports, TMPRSS2 has been 
shown to preferentially cleave H1N1, and to a lesser degree, H3N2. Hatesuer et al. 
revealed that viral titers in H1N1 infected TMPRSS2-deficient mice were significantly 
reduced compared to wild type animals (119). Furthermore, this group reported that while 
H3N2 replicated at similar levels in both knockout and wild type mice, the knockout 
mice had increased survival and body weight post-H3N2 infection (119).  
 Recent reports have further expanded on the HA-specificity of TMPRSS2. One 
group demonstrated that TMPRSS2 knockout mice were protected from lethal H1N1 but 
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not lethal H3N2 infection, while another group showed that TMPRSS2 knockout mice 
were protected against both H1N1 and H3N2 infection (120, 121).  These opposing 
findings suggest that HA activation not only depends on HA structure, but can vary 
amongst different viral strains bearing the same HA subtype. Despite these differences, 
there is substantial evidence implicating TTSPs in IAV pathogenesis.  
 Antiproteases are a broad class of proteins that inhibit proteases and modulate 
immune responses in the lung. Respiratory antiproteases are comprised of four families: 
tissue inhibitors of metalloproteinases (TIMPs), serpins, trappin-2/elafin, and secretory 
leukocyte protease inhibitor (SLPI). Each antiprotease family has unique target 
substrates, cellular sources, and antiprotease function (Table 1-2). TIMPs are produced 
by alveolar epithelial cells and alveolar macrophages (122). TIMPs inhibit MMP activity 
through the formation of an N-terminal reactive ridge domain that inserts into the active 
site of the target MMP (123, 124). In the context of viral infection, over-expressing 
TIMP-1 blocks RSV syncytia formation (125) . However, since MMP activity is not 
implicated in viral activation and infection, there are limited studies that investigate the 
direct anti-viral effects of TIMPs. 
 Serine protease inhibitors (serpins) are the largest and most broadly distributed 
superfamily of protease inhibitors. The majority of serpins inactivate serine proteases, but 
a small portion of serpins also inhibit caspase and cysteine proteases (126, 127).  Serpins 
exert their antiprotease activity by undergoing irreversible conformational changes that 
allow for the interaction and inactivation of serine proteases. To inhibit protease activity, 
serpins form long, flexible reactive center loops (RCL) that insert into the active site of 
the targeted protease. These RCL structures form above the serpin framework and allows 
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for the N-terminal portion of the RCL to insert into the protease active site. At this time, 
the protease and serpin remain covalently linked, the protease structure is 
conformationally changed, and the protease activity is significantly reduced (128). This 
action leads to the permanent deactivation of both serpin and protease, often described as 
a “suicide” event.   
 SerpinA1 encodes the most abundant antiprotease in the lung, alpha-1 antitrypsin 
(α-1AT). Point mutations of α-1AT generates a mis-folded version of this protein, 
resulting in an α-1AT deficiency (129). α-1AT deficient individuals are at a high risk for 
developing liver disease, emphysema, and COPD (130, 131). Respiratory epithelial cells 
secrete α-1AT in both the apical and basolateral compartments of the cell (132). 
Additionally, serpins have been shown to block viral entry of enveloped viruses such as 
human immunodeficiency virus (HIV) and herpes simplex virus (133, 134). Smee et al. 
showed that in vitro serpin antithrombin III treatment inhibited IAV infection nearly 100 
fold more than ribavirin, a nucleoside inhibitor used to halt IAV replication (135). The 
authors found that this effect was dependent on viral HA with decreasing efficacy in 
order of H1N1>H3N2>H5N1 (135). These data suggest that that serpin activity may 
parallel the TTSP activity, which is dependent on amino acid sequence, protein structure, 
and/or HA substrate accessibility.  
 Trappin-2 is a cationic 9.9kDa serine antiprotease secreted into the lung as a non-
glycosylated pre-protein. Upon proteolytic cleavage, trappin-2 is converted to elafin, a 
6kDa protein. Structurally, trappin-2 and elafin contain a cysteine-rich region, joined by 
four disulfide bonds, termed the whey acidic protein domain (WAP) (136). The structure 
of elafin is divided into two regions, the C-terminal region, which comprises the 
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antiprotease active site,  and N-terminal region, which allows for interactions with ECM 
proteins (137). Elafin specifically inhibits NE and preoteinase-3, and is secreted from 
tracheal epithelial cells, Clara cells, type II cells, and alveolar macrophages (138, 139). 
  Trappin-2 and elafin function as alarm antiproteases, as both are produced in 
response to inflammatory stimuli (140). In respiratory epithelial cells, elevated elafin 
levels are protective against recombinant NE treatment and products derived from 
activated human neutrophils in vitro (141). The elafin promoter is regulated by 
extracellular signal-regulated kinase, a component of the MAPK pathway and Rel-A, a 
mediator involved in NF-κB signaling (142, 143). In addition to functioning as an alarm 
antiprotease, elafin possesses antimicrobial effects. Ghosh et al. revealed that 
recombinant elafin was protective during HIV infection only when elafin was pre-
incubated with HIV, suggesting that elafin directly interacts with HIV virion and prevents 
viral infection (144). Interestingly, this group found that secreted elafin levels were 
elevated in the cervico-vaginal lavages of HIV-negative women compared to HIV-
positive women, albeit not statistically significant, suggesting that elafin secretions may 
be decreased after HIV infection. Similarly, after HRV infection, elafin is down-regulated 
in subjects with COPD (145).  Furthermore, elafin has been identified as a biomarker for 
acute respiratory distress syndrome (ARDS) (146). These findings suggest that elafin 
functions as an alarm mediator and may be decreased after viral infection. 
 SLPI is an additional alarm antiprotease that is highly expressed by epithelial 
cells, neutrophils, and macrophages. SLPI can be detected in respiratory secretions, 
saliva, seminal fluid, cervical mucus, tears, and cerebral spinal fluid (147, 148). 
Comprised of two closely related domains, the tertiary structure of SLPI resembles a 
17 
 
boomerang (149). Similar to the trappin family, SLPI contains a cysteine-rich WAP C-
terminal domain that is responsible for protease inhibition as well as the N-terminal 
domain that stabilizes the protease/antiprotease complex and exerts antimicrobial activity 
(150). The C-terminal active site, which confers antiprotease activity, is comprised of 
leucine and methionine residues (151, 152). 
 The main function of SLPI is to inhibit serine proteases such as NE (its main 
target), cathepsin G, elastase, chymase (153, 154). SLPI further contributes to respiratory 
host defense by modulating inflammation and inducing wound healing. SLPI exerts 
cellular anti-inflammatory effects by preventing the degradation of regulatory 
components of the NF-κB pathway and by directly competing for NF-κB binding sites in 
the promoter regions of pro-inflammatory cytokines such as IL-8 and tumor necrosis 
factor-α (TNF-α) (155-157). SLPI is also implicated in wound healing as reported by 
Ashcroft, et al. who investigated the role of SLPI in a mouse model of dermal wounds. 
Using this model, the authors found that SLPI knockout mice had impaired wound 
healing due to increased NE activity (158).  
 SLPI possesses broad antimicrobial effects. The N-terminal domain of SLPI 
possesses extracellular antibacterial activity by disrupting Staphylococcus aureus and 
Escherichia coli membranes (159). Additionally, SLPI binds to Opa protein of Neisseria 
gonorrhoeae, which leads to the lysis of bacterial membranes (160). Fahey et al. reported 
that increased extracellular SLPI secretions were correlated with elevated bactericidal 
activity and treatment with an anti-SLPI antibody significantly diminished bactericidal 
activity (161). SLPI has been shown to exert intracellular antibacterial effects by 
disrupting translation of E.coli during bacterial replication (162). Furthermore, SLPI 
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exerts fungicidal and fungistatic activity towards Aspergillus fumigatus and Candida 
albicans that is also dependent on the N-terminal domain of SLPI (163).    
 In the context of viral infections, SLPI inhibits HIV, human papillomavirus 
(HPV), and respiratory viruses. McNeeley et al. first detailed the anti-HIV activity of 
SLPI in human saliva (164). The authors demonstrated that SLPI was highly expressed in 
the saliva and inhibited HIV infection in monocytes and T cells in dose dependent 
fashion. Further studies revealed that SLPI exerts anti-HIV properties not through direct 
interaction with the virus, but rather through interacting with the target host cell (165). 
However, this group found that despite decreasing viral load, SLPI did not alter the 
infectivity of progeny virions, suggesting that SLPI inhibits HIV at the early stages of 
viral infection (166).  
 SLPI is also associated with protection from HPV, with two recent studies 
demonstrating that high levels of SLPI, possibly induced by cigarette smoking, correlate 
with protection against HPV infection (167, 168). Additionally, SLPI is induced and 
protective during respiratory virus infection. Kido et al. first demonstrated that SLPI 
decreased infectivity of IAV and Sendai viruses (169). Moreover, reports have revealed 
that intranasal administration with recombinant SLPI (rSLPI) decreased progeny virus 
nearly 3,000 fold compared to vehicle treated mice infected with mouse-adapted IAV 
(170). Furthermore, the authors also reported that in mice administered rSLPI, nearly all 
the progeny viruses released from infected cells were secreted as non-infectious HA0 
precursor virions (170). Additionally, we have shown that recombinant human SLPI 
inhibits IAV replication in vitro (171).  
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 Although SLPI contributes to respiratory host defense by decreasing 
inflammation and infection, SLPI can also induce pro-inflammatory responses. Mulligan 
et al. demonstrated that post-translational modifications of SLPI increased IL-8 secretion, 
neutrophil recruitment, and vascular permeability (172). Extracellular SLPI can be post-
translationally modified by respiratory proteases such as cathepsin L, MMP12, chymase, 
and NE, resulting in cleavage of SLPI (76, 87, 173, 174). Cleaved SLPI levels are 
elevated in COPD patients during respiratory infection, which renders SLPI non-
functional (72, 145, 175).  Moreover, we have shown that in NLF from smokers, SLPI is 
post-translationally processed and cleaved (Chapter 2)  (176). Oxidative stress, which can 
be derived from reactive oxygen intermediates or environmental exposures such as 
cigarette smoke, modifies the active site and decreases the antiprotease properties of 
SLPI (177, 178). While SLPI exerts powerful protective effects in the respiratory tract, 
post-translational alterations and/or oxidative modifications can drastically shift the 
activity of SLPI towards potentially damaging effects.    
 The protease/antiprotease balance is a delicate interaction of enzymes and 
proteins that are involved in respiratory function. In the healthy lung, proteases maintain 
tissue homeostasis, and their activities are regulated by antiproteases. A shift in the 
balance towards increased protease expression and activity can lead to overt 
inflammation and the development of chronic lung disorders such as COPD and 
emphysema (71, 72). Moreover, respiratory serine proteases, such as the TTSP family, 
activate a variety of respiratory viruses for enhanced rates of viral infection. Additionally, 
antiproteases, such as SLPI, inhibit the function of serine proteases and block viral entry 
into the target cell. As such, the protease/antiprotease balance is not only a critical 
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component for respiratory homeostasis but also is a powerful determinant of respiratory 
viral pathogenesis.    
1.3 Respiratory viruses infect respiratory epithelial cells and cause respiratory 
exacerbations  
 Respiratory epithelial cells are the primary targets for respiratory viral infection 
based on extracellular ligands and residues that are found on these cells. More than 200 
antigenically different viruses infect respiratory epithelial cells (179). These viruses 
include coronaviruses, rhinoviruses, metapneumoviruses, enteroviruses, adenoviruses, 
respiratory syncytial viruses, measles virus, parainfluenza viruses, and influenza viruses. 
These respiratory viruses differ in genome composition, viral structure, target cell type, 
and sensitivity to components of the respiratory protease/antiprotease balance (Table 
1-3).  
 Upon viral infection, respiratory epithelial cells replicate viral genomes and 
propagate infectious virions for productive viral infection. Additionally, respiratory 
epithelial cells mount intracellular immune responses to warn neighboring cells as well as 
orchestrate recruitment of immune cells to sites of infection (180). The respiratory 
epithelium also secretes soluble mediators such as TTSPs and SLPI, which are implicated 
in viral infection. Many respiratory viruses are sensitive to TTSP-dependent cleavage 
such as coronaviruses, metapneumoviruses, parainfluenza viruses, and influenza viruses 
(Table 1-3). However, while some respiratory viruses, such as coronaviruses, induce 
antiprotease expression, only parainfluenza and influenza are sensitive to SLPI activity 
(Table 1-3). As such, investigating the role of the protease/antiprotease balance in the 
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context of a parainfluenza or influenza infection could elucidate mechanisms and 
strategies to prevent viral infections.  
 We are interested in investigating the role of the protease/antiprotease balance in 
the context of an influenza infection since influenza infects 2-5 million people worldwide 
each year and can cause worldwide pandemics, as seen with the recent 2009 H1N1 strain 
(181). Moreover, in the US alone, over 20,000 people die due to influenza infection and 
related complications (182). Influenza remains a significant public health burden due to 
yearly virus mutations and reassortment and the ability of the virus to infect a wide range 
of hosts.  Despite large-scale vaccination programs and the development of anti-viral 
therapeutics, influenza-associated morbidity and mortality rates have not changed in 
recent years (183). As such, examining strategies, such as modulating the 
protease/antiprotease balance, may serve as alternative target to prevent influenza 
infection. 
1.3.1 Influenza virus components and viral life cycle 
 Influenza is comprised of three subtypes: influenza A, B, and C. All subtypes are 
able to infect humans, but IAV is the most common due to the large host range. 
Moreover, IAV mutates at higher rates than the other influenza subtypes (184). IAV is a 
negative sense, enveloped RNA virus that contains a segmented genome comprised of 
eight genes that encodes 10 viral proteins (185). The largest proteins, polymerase basic 
protein (PB) 2, PB1, and polymerase acidic protein, form the viral polymerase and 
transcribe viral mRNA to positive sense cRNA. The cRNA serve as templates to for viral 
replication. HA is the viral envelope protein critical for virus attachment and entry into 
host cells. The viral nucleoprotein is important for forming complexes between the viral 
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RNA segments.  For viral egress, the viral neuraminidase protein cleaves the interaction 
between sialic acid residues located on newly formed virions and host cell glycoproteins.  
 The matrix (M) gene encodes two proteins, M1 and M2. M1 is important for viral 
structure, forming a layer between the viral core and viral envelope, while M2 is critical 
for viral entry into host cytoplasm. Upon low pH, M2 becomes activated, inserts into the 
endosomal membrane, functioning as an ion channel to induce fusion and uncoating. The 
last IAV gene includes the non-structural gene (NS) that encodes two proteins, NS1 and 
NS2 (186). NS1 regulates mRNA splicing and translation and is involved in virus evasion 
from host anti-viral responses. NS2 aggregates viral RNA and mediates export of newly 
synthesized viral proteins from the nucleus to allow for viral progeny assembly (187). 
1.3.2 HA must be proteolytically cleaved for productive IAV infection 
 For IAV to infect cells, the viral membrane protein HA must be proteolytically 
cleaved and activated by respiratory serine proteases. HA resides on the virion as a 
fusion-inactive precursor (HA0), and upon proteolytic cleavage, a fusion-active trimer 
with disulfide-linked HA1 and HA2 subunits, is generated (105, 107, 188, 189). After 
entry into the cell, the virion enters endosomal compartments and upon acidification of 
the endosome, viral and host membranes fuse together. The membrane fusion allows for 
viral entry into the cell, so viral replication can initiate (190).  
 Most HA0 will be cleaved at either a single arginine or lysine residue to generate 
active HA1 and HA2. For low-pathogenic IAV strains, respiratory trypsin-like serine 
proteases cleave at monobasic arginine or lysine residues (106, 191). However, highly 
pathogenic avian influenza viruses possess multibasic cleavage sites that can be cleaved 
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by ubiquitous intracellular furin-like serine proteases (192, 193). This difference in HA 
cleavage motifs increases susceptibility for systemic, wide-spread infection to sites such 
as the central nervous system rather than localized, restricted infection to sites such as the 
respiratory tract. As such, investigating strategies to block protease-induced HA 
activation and increase antiprotease activity may serve as a potential approach to protect 
against IAV infection.  
1.4 Cigarette smoking is a risk factor for influenza infection 
1.4.1 Cigarette smoking decreases respiratory host defense responses to influenza 
infection 
  We have previously shown that in vitro differentiated nasal epithelial cells from 
smokers have increased levels of IAV replication, which was attributed to dampened 
activation of innate immune signaling pathways (194). Moreover, our group has 
investigated the effects of cigarette smoking on influenza infection in vivo using the 
FDA-approved live-attenuated influenza virus vaccine (LAIV). Nasal lavage fluid (NLF) 
collected from smokers inoculated with LAIV had elevated markers of viral replication as 
well as depressed levels of innate immune mediators, such as IL-6, compared to non-
smokers (195). Additionally, our group has shown that this increased in viral replication 
may be due to deficient NK cell and gamma delta T cell activation and function (196, 
197). Our studies have been corroborated with large epidemiological studies. After the 
1968 IAV Hong Kong epidemic, Finklea at al. reported that heavy smokers and light 
smokers had 21% and 10% increase in influenza infection, respectively (198). Moreover, 
studies conducted in military bases and in elderly populations revealed that cigarette 
smoke increased incidences and severity of influenza infection (199, 200).   
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1.4.2 Cigarette smoking induces oxidative stress on the respiratory epithelium 
 We and others speculate that the increased risk for infection in smokers is tightly 
linked to increased rates of oxidative stress (201, 202). The respiratory epithelium is 
constantly being exposed to inhaled insults, which results in the generation of reactive 
oxygen species, free radicals, and peroxides (203). While these byproducts are 
indispensable for many biological processes, too many of these byproducts can result in 
oxidative stress. Oxidative stress has been associated with the development of disorders 
including cancer, cardiovascular diseases, neurodegenerative diseases, and chronic 
inflammation (204, 205).  
 As such, cells are equipped with various mechanisms, such as antioxidant 
responses, to block these damaging effects (206, 207). One mechanism involves nuclear 
factor (erythroid-derived 2)- like 2 (Nrf2). Nrf2 is a key transcription factor involved 
regulating intracellular redox status (208, 209). In the absence of inducers, Nrf2 is 
sequestered in the cytoplasm by kelch-like ECH-associated protein 1 (Keap1) (210). 
However, upon stimulation, Nrf2 is released from Keap1, and Nrf2 translocates into the 
nucleus and binds to antioxidant response elements (ARE). ARE binding sites are located 
on the promoter regions of phase II enzymes such as NADPH quinone oxidoreductase 1 
(NQO1) and heme oxygenase-1 (HO-1) (211). The Nrf2-dependent phase II response has 
been implicated in the development of chronic lung diseases since antioxidant capacity 
and Nrf2 protein levels are decreased in the lungs of COPD patients (212).  
 These protective effects of Nrf2 effects are corroborated in animal studies. Nrf2 
deficient mice cannot induce antioxidant genes, display elevated levels of oxidative 
stress, and exhibit decreased antioxidant capacity (213). Iizuka et al. reported that Nrf2-
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deficient mice exposed to cigarette smoke developed emphysema-like qualities and were 
unable to induce antiproteases such as SLPI (214). SLPI contains ARE regions on its 
promoter, suggesting that oxidative stress responses modulate SLPI regulation. We have 
shown that intracellular SLPI is alternatively regulated in the respiratory epithelium of 
smokers, further supporting the findings that oxidative stress modifies respiratory host 
defense responses (Chapter 2)  (176). These data demonstrate that Nrf2 is a central 
mediator that regulates respiratory epithelial responses to oxidative stress. Moreover, it is 
evident that cigarette smoke impairs both Nrf2 signaling and antiproteases regulation and 
function in the lung.  
1.4.3 Cigarette smoke modulates the protease/antiprotease balance 
 Cigarette smoking shifts the protease/antiprotease balance, in favor for increased 
protease expression and activity, which increases susceptibility to viral infection (72, 215, 
216). Long-term cigarette smoke exposure in mice, in tandem with RSV infection, 
resulted in elevated levels of lung inflammation and protease expression (217). Gualano 
et al. reported increased protease expression and activity in the lungs of cigarette 
exposed, IAV infected mice (218). Other groups have further expanded these findings, 
demonstrating that Nrf2-deficient mice exposed to cigarette smoke infected with IAV had 
increased inflammation as well as elevated rates of mortality compared to wild type, 
cigarette exposed infected mice (219). These studies implicate the role of the 
protease/antiprotease balance during viral infection in the context of cigarette smoke 
exposure.   
 However, while many studies have explored the effects of cigarette smoke on 
respiratory infections in animal models, only a small fraction of investigations have 
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examined the effects of smoking on respiratory infections in humans. Single nucleotide 
polymorphisms in genes involved in the protease/antiprotease such as SerpinA1, 
SerpinE2, MMP9, and MMP12 have been identified as candidate genes implicated in the 
development of COPD or emphysema, chronic lung conditions that are associated with 
increased risk for respiratory infection (220-222). Additionally, we have demonstrated 
that exposure to inhaled oxidants, such as ozone gas, increases TMPRSS2 and HAT 
release and decreases SLPI secretion. Furthermore, we found that this altered 
protease/antiprotease balance resulted in elevated levels of HA cleavage and increased 
viral entry into ozone-exposed epithelial cells (171). These findings highlight the effects 
of oxidant exposure on the protease/antiprotease balance in the context of viral infection 
using relevant human models.   
1.4.4 Cigarette smokers are immunosuppressed   
 In addition to increased oxidative stress and altered protease/antiprotease balance, 
smokers are deficient in many dietary vitamins and minerals (223). In a national study of 
over 7800 healthy adults including smokers or nonsmokers, Wei et al. found that smokers 
had lower serum levels of vitamin C, alpha- and beta-carotene, and lutein (224). 
Additionally, they reported a slight reduction in serum vitamin E, lycopene, and selenium 
levels. Moreover, this group identified that smokers had significantly lower dietary 
intakes of beta-carotene and vitamin C. These findings have been supported by other 
groups (225). Examining bronchoalveolar lavage fluid, Pacht et al. showed vitamin E 
levels were decreased in smokers (226). These data suggest that smokers may suffer from 
additive bad health habits (i.e. smoking and poor nutrition), further increasing the pro-
oxidant status and enhancing their risk for respiratory infection. 
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1.5 Nutritional supplementation can decrease oxidative stress and protect against 
IAV infection 
 Nutritional supplementation could serve as a low-cost, convenient strategy to 
reduce oxidative stress, restore the protease/antiprotease balance, and protect against 
infection. Additionally, nutritional supplementation could function as an intervention in 
nutritionally deficient populations such as smokers (225). Potential nutritional 
antioxidants that have been investigated include vitamins, trace elements, and 
antioxidants. Though vitamins have been shown to reduce inflammation and oxidative 
stress, research regarding the anti-viral properties of vitamins in humans remains tenuous. 
The link between respiratory infection and vitamins C and D have been researched for 
decades, with many studies revealing mixed results (227-230).  
1.5.1 The effects of vitamins and trace elements on IAV infection in vivo 
 Isolated in the 1930s, vitamin C is one of the most famous nutritional supplements 
thought to prevent respiratory infection. However, a thorough meta-analysis recently 
conducted for the Cochrane Library by Hemila et al. examined twenty-nine trials, with 
over 11,000 study subjects enrolled in a supplementation study of 0.2g/day or more of 
vitamin C, found that there was no evidence that vitamin C reduced the incidence or 
severity of the common cold (227). The anti-viral effects of vitamin D have also resulted 
in inconclusive or negative results. Sparked by the seasonality of influenza, researchers in 
the 1980s proposed that the decrease in sun exposure contributed the influenza infection. 
Sun exposure triggers vitamin D production in the skin and lack of exposure decreases 
vitamin D levels and can lead to vitamin D deficiency. However, randomized 
supplementation of 1000 IU/day of vitamin D in over 2,200 adults did not significantly 
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reduce incidence or duration of upper respiratory tract infection (228). These findings 
suggest that vitamin C or D supplementation do not significantly reduce the incidence or 
severity of respiratory virus infection. 
 Contrary to vitamin C and D, minerals such as zinc and selenium possess potent 
anti-viral properties. A double-blind placebo controlled trial using zinc lozenges before or 
after HRV challenge revealed that zinc treatment significantly reduced clinical scores of 
HRV infection (231). Furthermore, an Intervention Review on zinc treatment for the 
common cold was conducted for the Cochrane Library. Singh et al. analyzed data from 
nearly 20 trials and over 1,700 participants and found that zinc was associated with 
significant reduction in the duration of common cold symptoms (232).   The anti-viral 
effects of zinc are thought to be mediated by decreasing receptors necessary for 
respiratory virus attachment, demonstrating the broad anti-viral properties of zinc in 
response to respiratory virus infection (233).  
 Another effective anti-viral trace element includes selenium (234-236). Selenium 
is necessary for the formation of nearly 25 selenoproteins, including glutathione 
peroxidases, thioredoxin reductases, and other selenoproteins (237). A 12 week human 
dietary intervention study in 119 individuals who received placebo or selenium treatment 
had increased selenoprotein S1 mRNA after influenza vaccine challenge (238). Our 
group has shown that differentiated nasal epithelial cells (NEC) grown in either selenium 
replete or selenium deficient media have altered MUC5AC mRNA levels. After IAV 
infection, the selenium deficient cells had increased IL-6 and markers of cell death but 
did not have altered levels of viral replication (239). While these reports suggest the 
protective effects of minerals such as zinc and selenium, there are drawbacks to using 
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these supplements as daily interventions due to potential cellular toxicity, especially for 
trace elements such as selenium.  
1.5.2 Antioxidants are an attractive strategy to induce host defense and protect against 
infection 
 Antioxidants have garnered much attention due to the inhibition of respiratory 
oxidative stress and inflammation (240). Antioxidants are a broad class of molecules that 
can be found in a variety of foods and exert potent host defense effects. One potent class 
of antioxidants includes flavonoids.  Flavonoids are nonessential, polyphenolic 
phytonutrients that occur naturally in many plant-based foods and possess profound 
effects on human health, including decreasing oxidative stress (241). Over 8,000 
flavonoid compounds have been identified, and they can be broken down into six groups: 
flavonols, flavones, isoflavones, flavanones, anthocyanidins, and flavan-3-ols (242).  
Flavan-3-ols (or commonly referred to as flavanols or catechins) are the most common 
flavonoid consumed in the American diet and can be found in red wine, tea, apples, 
grapes, and chocolate (243). 
 Flavan-3-ols found in green tea, such as epigallcatechin-3-gallate (EGCG), have 
been studied extensively in the context of a viral infection. EGCG has been shown to 
bind to CD4 T cell receptors and prevent interaction with the HIV envelope protein, 
gp120 (244). As such, the use of EGCG as an anti-HIV therapeutic has entered 
preclinical investigation. Nance et al. showed that EGCG was able to inhibit HIV 
infection of human T cells and macrophages at physiologic doses (245).  Furthermore, 
EGCG possesses potent anti-influenza properties. EGCG agglutinates influenza viruses 
and inhibits viral replication, which depended on influenza subtype (246, 247). Ling et al. 
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corroborated these findings showing that oral administration of EGCG in mice infected 
with influenza had nearly a 50% decrease in viral titers and a 50% increase in survival 
rates (248).  Using in vitro human models, we have also shown that EGCG blocks 
influenza entry and viral replication in differentiated NEC (249). As such, antioxidant 
supplementation with flavan-3-ols may serve as an attractive anti-viral therapy.  
1.5.3 Sulforaphane (SFN), a nutritional antioxidant, modulates the protease/antiprotease 
balance and protects against IAV infection 
 Another potent antioxidant is SFN, an isothiocyanate that induces respiratory host 
defense by decreasing oxidative stress and inflammation. SFN is derived from the 
hydrolysis of glucosinolates found in cruciferous vegetables such as broccoli, brussel 
sprouts, and cabbage. Using in vitro models of respiratory epithelial cells, SFN 
supplementation enhances Nrf2 activity, induces cellular antioxidants, such as HO-1 and 
NQO1, and inhibits pro-inflammatory cytokine release (250-253). Furthermore, Riedl et 
al. reported that in vivo SFN supplementation enhanced respiratory phase II enzyme 
expression, indicating that nutritional SFN supplementation induces respiratory 
antioxidant responses (254).   
 Beyond its antioxidant function, SFN may have important functions in 
modulating components of the protease/antiprotease balance. We have shown that SFN 
supplementation induces SLPI transcriptionally, resulting in increased SLPI secretion in 
the nasal mucosa in an Nrf2-dependent fashion (Chapter 4) (255). SFN also inhibits 
MMP expression and inflammation in using animal models of central nervous system 
injury as well as in breast cancer cell lines (256-258). SFN decreases TTSPs, such as 
TMPRSS2, by down-regulating AR signaling, a receptor involved regulation of 
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TMPRSS2 expression (259). Recent reports from Schultz et al. have confirmed and 
expanded these findings showing that Nrf2 negatively regulates AR transactivation of 
androgen response genes such as TMPRSS2 (260). The authors found that nuclear factor 
(erythroid-derived 2)- like 1, a cytoplasmic transactivator of AR, is sequestered in the 
nucleus when Nrf2 is induced. These data show that SFN increases SLPI secretion and 
decreases TMPRSS2 expression in a variety of models (Figure 1-2). 
 SFN also exerts broad antimicrobial effects. SFN supplementation of alveolar 
macrophages from COPD patients increases clearance of Pseudomonas aeruginosa (261). 
Further, SFN elevates bacterial detection and induces phagocytosis in alveolar 
macrophages from COPD patients, which is dependent on Nrf2 activation (261). 
Additionally, SFN is protective against respiratory viruses such as IAV. We have shown 
that SFN decreases IAV replication by reducing IAV entry into respiratory epithelial cells 
(249). Furthermore, our group recently showed that sulforaphane-containing broccoli 
sprouts significantly decreased IL-6 and markers of viral replication in NLF from 
smokers post-LAIV inoculation (262). These results indicate that SFN may be a safe, 
low-cost intervention for decreasing influenza infection in susceptible populations such 
as smokers. We hypothesize that the anti-IAV effects of SFN may be mediated in a two 
pronged approach: 1) by inducing SLPI into the nasal mucosa, which protects against 
influenza entry into respiratory epithelial cells and 2) by decreasing TMPRSS2 secretion, 
which decreases HA activation and IAV replication (Figure 1-3).  
1.6 Summary  
 It is evident that the protease/antiprotease balance is important for regulating 
respiratory viral infection. This balance includes the TTSP family, proteases involved in 
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HA-activation and SLPI, a serine antiprotease found highly expressed in the respiratory 
tract. Moreover, oxidants, such as cigarette smoke, and antioxidants, such as SFN, 
directly and indirectly alter the protease/antiprotease balance. In the subsequent chapters, 
I will describe how protease/antiprotease balance is modified by oxidants and nutritional 
antioxidants, which determines influenza susceptibility. These results will help to identify 
potential targets and therapeutics to limit respiratory IAV infection, especially in 
susceptible populations such as smokers. 
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Proteases in the 
respiratory 
tract Target substrates 
Sources in the 
lung Activity 
Cathepsin B, K, 
L, and S 
Elastin, laminin, 
antiproteases, MHC 
II, respiratory viruses 
(75-78) 
Bronchial 
epithelial cells, 
macrophages, 
dendritic cells 
(74, 263) 
Cysteine proteases 
with cysteine serving 
as a nucleophile for 
target motifs 
MMP1, 2, 3, 7, 
8, 9, 12, and 13 
Collagen, elastin, 
inflammatory 
cytokines such as IL-
1β and IL-8, 
defensins, 
antiproteases (83, 84, 
264) 
Epithelial cells, 
alveolar 
macrophages, 
monocytes, 
neutrophils, 
mast cells, 
eosinophils 
(265-267) 
Metal endopeptidases 
with conserved zinc 
binding site 
Neutrophil-
derived proteases 
(NE, cathepsin 
G, proteinase 3) 
Elastin, collagen, 
fibronectin, laminin, 
proteoglycans, 
immunoglobulins, 
complement 
components, T cell 
receptors. 
antiproteases (174, 
176, 268-273) 
Mature 
neutrophils 
(274) 
Serine proteases with 
conserved catalytic 
triad of serine, 
aspartic acid, and 
histidine 
TTSPs 
Fibrinogen, 
urokinase, respiratory 
viruses (98, 99, 104, 
105, 117) 
Epithelial cells 
(93) 
Serine proteases with 
conserved catalytic 
triad of serine, 
aspartic acid, and 
histidine 
Table 1-1. Target substrates, sources, and activity of respiratory proteases. 
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Antiproteases in 
the respiratory 
tract Target substrates 
Sources in the 
lung Activity 
TIMPs MMPs (124) 
Alveolar 
epithelial cells, 
alveolar 
macrophages 
(122) 
Insert reactive ridge 
N-terminal domain 
into MMP active site, 
inhibit apoptosis (123, 
275) 
Serpin 
Serine and cysteine 
proteases, caspases, 
bacteria, viruses 
(126, 127, 133, 134, 
276) 
Epithelial cells, 
alveolar 
macrophages 
(132, 277, 278) 
Insert RCL into the 
active site of the 
targeted protease, 
inhibit LPS-induced 
inflammation, block 
microbial infection 
(128, 279) 
Trappin/Elafin 
NE and proteinase-3, 
enveloped viruses 
(280) 
Tracheal 
epithelial cells, 
Clara cells, 
type II cells, 
alveolar 
macrophages 
(139) 
Contain WAP domain 
for antiprotease 
activity, inhibit viral 
infection (138, 144, 
281, 282) 
SLPI 
NE, cathepsin G, 
chymase, bacteria, 
and viruses (153, 
154) 
Epithelial cells, 
neutrophils, 
macrophages 
(149, 176) 
Contain WAP domain 
for antiprotease 
activity, antimicrobial 
effects due to N-
terminal domain and 
high cationicity, block 
inflammatory 
cascades, inhibit viral 
infection (138, 155-
157, 169, 171, 281, 
282) 
Table 1-2. Target substrates, sources, and activity of respiratory antiproteases. 
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Respiratory virus 
Genome; 
structure Target cell 
Require 
proteolytic 
cleavage by 
secreted 
respiratory 
proteases? 
Sensitive to 
secreted 
respiratory 
anti-
proteases? 
Adenovirus 
dsDNA; 
Non-
enveloped 
Epithelial cells 
using clathrin-
dependent entry 
mechanisms 
(283) 
No No 
Rhinoviruses 
+ssRNA; 
Non-
enveloped 
Epithelial cells 
of the upper 
airway 
expressing 
ICAM-1 (21) 
No No 
Enteroviruses 
+ssRNA; 
Non-
enveloped 
Epithelial cells 
expressing 
ICAM-1 or DAF 
(284) 
No No 
Coronaviruses 
+ssRNA; 
Enveloped 
Epithelial cells 
expressing 
ACE2 or DPP4 
(285, 286) 
Yes- cleave 
S protein (78, 
104, 118, 
287-290) 
Yes (291, 
292) 
Measles viruses 
-ssRNA; 
Enveloped 
Epithelial cells 
expressing nectin 
4 (293, 294) 
No No 
Metapneumoviruses 
-ssRNA; 
Enveloped 
Upper and lower 
airway epithelial 
cells expressing 
αVβ1 integrin 
(22) 
 
Yes- cleave 
F 
protein (117) 
No 
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Respiratory 
syncytial viruses 
-ssRNA; 
Enveloped 
Epithelial cells 
expressing 
sulfated 
glycosamino-
glycans (295) 
No No 
Parainfluenza 
viruses 
-ssRNA; 
Enveloped 
Epithelial cells 
expressing 2,3 or 
2,6 linked sialic 
acid residues 
(296) 
Yes- cleave 
F protein 
(297, 298) 
Yes (169, 
298, 299) 
Influenza viruses 
-ssRNA; 
Enveloped 
Epithelial cells 
expressing 2,3 or 
2,6 linked sialic 
acid residues 
(300) 
Yes- cleave 
HA protein 
(101, 105, 
107, 118-
121, 188, 
290, 301, 
302) 
Yes (169-
171, 303) 
Table 1-3. Genome and structure, target cell type, and sensitivity to protease/antiprotease 
balance of respiratory viruses. 
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1. Respiratory epithelial cells form a physical and mechanical barrier to protect against 
respiratory stimuli. 2. Respiratory epithelial cells express receptors and ligands that 
interact with neighboring epithelial cells, respiratory immune cells, and inhaled stimuli 
such as respiratory pathogens. 3. Respiratory epithelial cells secrete soluble factors such 
as cytokines, chemokines, and antimicrobial peptides to contribute to respiratory host 
defense. 
  
Figure 1-1. Respiratory epithelial cells function as an “orchestrator” to initiate, 
coordinate, and respond to inhaled stimuli.  
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SFN enters the cell and induces Nrf2 release from its cytoplasmic repressor, Keap1. Nrf2 
translocates into the nucleus and binds ARE regions on various cytoprotective promoters. 
SLPI contains ARE sites on its promoter and SFN induces Nrf2-dependent activation of 
SLPI. Additionally, SFN decreases TTSP expression such as TMPRSS2. 
  
Figure 1-2. SFN dampens inflammation, alleviates oxidative stress, and alters the 
protease/antiprotease balance.  
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Figure 1-3. The protease/antiprotease balance regulates IAV infection and can be 
modulated by SFN supplementation.  
For entry into target host cells, the HA protein on the IAV virion must be proteolytically 
cleaved from HA0 (purple) into fuso-active HA1 and HA2 proteins (blue). Respiratory 
serine proteases such as TMPRSS2, HAT, and matriptase have been implicated in HA 
activation and IAV infection, yet these effects seem to strain specific. While antiproteases 
such as SLPI inhibit serine protease activity and protect against IAV infection, it remains 
unknown what HA-activating protease is inhibited by SLPI and how SLPI mediates these 
effects. Lastly, SFN supplementation can be used to increase SLPI secretion, reduce 
TMPRSS2 secretion, and decrease viral entry and downstream IAV infection.  
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CHAPTER 2  
The regulation and activity of secretory leukoprotease inhibitor (SLPI) is altered in 
smokers
*
 
 
2.1 Overview 
 A hallmark of cigarette smoking is a shift in the protease/antiprotease balance, in 
favor of protease activity. However, it has recently been shown that smokers have 
increased expression of a key antiprotease, secretory leukoprotease inhibitor (SLPI), yet 
the mechanisms involved in SLPI transcriptional regulation and functional activity of 
SLPI remain unclear.  We examined SLPI mRNA and protein secretion in differentiated 
nasal epithelial cells (NEC) and nasal lavage fluid (NLF) from non-smokers and smokers 
and demonstrated that SLPI expression is increased in NEC and NLF from smokers. 
Transcriptional regulation of SLPI expression was confirmed using SLPI promoter 
reporter assays followed by chromatin immunoprecipitation. The role of STAT1 in 
regulating SLPI expression was further elucidated using WT and stat1
-/- 
mice.  Our data 
                                                 
*
Megan Meyer, Rebecca N. Bauer, Blanche D. Letang, Luisa Brighton, Elizabeth 
Thompson, Rosalia C. M. Simmen, James Bonner, Ilona Jaspers. First published in 
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demonstrate that STAT1 regulates SLPI transcription in epithelial cells and slpi protein in 
the lungs of mice. Additionally, we reveal that NEC from smokers have increased 
STAT1 mRNA/protein expression. Lastly, we demonstrate that SLPI contained in the 
nasal mucosa of smokers is proteolytically cleaved but retains functional activity against 
neutrophil elastase.  These results demonstrate that smoking enhances the expression of 
SLPI in NEC in vitro and in vivo and that this response is regulated by STAT1. In 
addition, despite post-translational cleavage of SLPI, anti-protease activity against 
neutrophil elastase is enhanced in smokers. Together, our findings show that SLPI 
regulation and activity is altered in the nasal mucosa of smokers, which could have broad 
implications in the context of respiratory inflammation and infection. 
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2.2 Introduction 
 Cigarette smoking is a significant public health burden and has been linked with 
various cancers, heart disease, infection, and respiratory pathologies (304, 305). Each 
year in the United States, cigarette smoking results in over $100 billion lost to cover 
healthcare and indirect costs (306).  In the context of the respiratory mucosa, a hallmark 
of cigarette smoking is a shift in protease/antiprotease balance, in favor of protease 
expression and activity, resulting in increased inflammation and pathology (72, 215, 216, 
269, 307, 308). As a potential balance to the increased protease expression and activity, 
recent studies indicate that a key antiprotease secretory leukoprotease inhibitor (SLPI) is 
elevated in smokers compared to non-smokers (309). Moreover, in patients with chronic 
obstructive pulmonary disease (COPD) and in patients with COPD and secondary 
bacterial infection, SLPI levels are elevated in the respiratory tract of these individuals 
(71, 145).  However, the mechanisms mediating this induction of SLPI in the respiratory 
tract of smokers and patients with COPD are not known.  
 The SLPI promoter contains many regulatory sites including interferon sensitive 
response elements (ISRE) binding sites (310). Thus, transcription factors activated by 
interferon signaling pathways, such as signal transducer and activator of transcription 1 
(STAT1), could be potential regulators of SLPI transcription by binding to ISRE and 
ISRE-like sites present in the SLPI promoter region. While STAT1 has not been 
examined in the context of cigarette smoking, recent studies demonstrate a positive 
correlation between STAT1 induction and COPD status, as well as elevation of 
downstream STAT1 dependent genes such as NOS2, suggesting enhanced STAT1 
activation and STAT1-dependent regulation of SLPI in smokers (311, 312).  
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 In addition to transcriptional regulation, extracellular SLPI can be post-
translationally cleaved by respiratory proteases such as cathepsins, matrix 
metalloproteinases, chymase, neutrophil elastase (NE), which can dramatically reduce 
SLPI activity (76, 87, 173, 174). Since increased protease levels are associated with 
smoking, this suggests that SLPI is cleaved and less active in smokers (72, 215, 216). 
Because cleaved SLPI can be pro-inflammatory, we believe examining extracellular SLPI 
cleavage and activity is important to understand the pathophysiology associated with 
smoking (145, 172).  
 Investigating differences in innate immune mechanisms in potentially susceptible 
subpopulations is important to understand the underlying mechanisms for enhanced 
pathology and disease. SLPI is a key antiprotease involved in respiratory homeostasis and 
antimicrobial responses. Understanding the mechanisms regulating SLPI transcriptional 
regulation in smokers is important since SLPI is a potent antiprotease in the lung and 
possesses anti-inflammatory and antimicrobial qualities. Based on the presence of ISRE-
sites in the promoter region of SLPI, we hypothesized that STAT1 may regulate SLPI 
expression in smokers. Using in vitro and in vivo approaches, we demonstrate that SLPI 
expression is enhanced in NEC from smokers, that the expression of SLPI is regulated by 
STAT1, and that the proteolytic cleavage of SLPI in smokers does not affect the anti-NE 
activity. 
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2.3 Materials and methods 
Study subjects and nasal lavage fluid (NLF) collection  
 14 healthy young adults (nine male and 5 female), seven non-smokers (29.2±7.2 
years old) and seven smokers (27.1±3.3 years old), as characterized by our previous 
studies, were recruited to participate in this study (197). Informed consent was obtained 
from all subjects and the protocol was approved by the UNC Biomedical Institutional 
Review Board. Table 2-1describes the demographic and cigarette smoking status of the 
participants. Nasal lavage was performed as previously described (255). NLF was 
filtered, centrifuged, and cell-free NLF supernatants were stored at -80C.  
Differentiated human nasal epithelial cells (NEC) and bronchial epithelial cell line. 
  Nasal epithelial cells (NEC) from non-smoker and smoker volunteers were 
obtained, expanded, and cultured as described by us previously (255) . Briefly, NECs 
were obtained from non-smokers (n=5) and smokers (n=5) by sampling the inferior 
surface of the turbinate with a Rhino-Probe curette (Arlington Scientific, Arlington, TX), 
which was inserted through a nasoscope. This protocol was approved by the University of 
North Carolina School of Medicine Institutional Review Board for Biomedical Research. 
Primary NEC were expanded to passage 2 then plated on collagen-coated filter supports 
with a 0.4 μM pore size (Trans-CLR; Costar, Cambridge, MA). Upon confluency, air 
liquid interface (ALI) culture conditions (removal of the apical medium) to promote 
differentiation was established as described by us previously (34). We obtained and grew 
bronchial epithelial cell line, BEAS-2B, as previously described (255). 
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qRT-PCR 
 Total RNA was extracted using TRIzol. First-strand cDNA synthesis and qRT-
PCR were performed using commercially available primers and probes (Applied 
Biosystems, Life Technologies, Carlsbad, CA) for SLPI, STAT1, and β-Actin. Gene-
specific mRNA levels were normalized to β-Actin mRNA levels. 
Western blotting 
 Cell lysates and apical washes from NEC as well as lung homogenates from wild 
type (WT) and stat1
-/- 
mice were harvested. In some experiments, 7.5ug of recombinant 
human SLPI (rhSLPI, R&D, Minneapolis, MN ) was incubated with 0.15U neutrophil 
elastase (NE, Enzo Life Sciences, Farmingdale, NY) at 37C for 30 minutes prior to 
analyses by Western blotting. All samples were separated by 15% SDS-PAGE and 
transferred to nitrocellulose. Proteins were detected using speciﬁc antibodies (Santa Cruz, 
Dallas, TX) to SLPI and STAT1 (1:1,000) or β-actin (1:2,000), which served as a loading 
control. Antigen-antibody complexes were incubated with horseradish peroxidase-
conjugated secondary antibody and were detected using chemiluminescence.  
SLPI ELISA 
 NLF was collected as described above and analyzed for SLPI protein using 
commercially available ELISA (R&D).  
SLPI transcriptional activation  
 BEAS-2B cells were seeded overnight and transfected using Lipofectamine® 
(Life Technologies) following manufacturer’s suggestions, as previously reported (255). 
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To measure SLPI transcriptional activation, a plasmid containing luciferase E under the 
control of the SLPI promoter, containing 1385 bp of the 5’ regulatory region on the 
porcine SLPI gene, was constructed (313).  Cells were transfected with 1μg SLPI-Luc and 
500 ng TK-Renilla for 24 hours. Cells were treated with 25μM AG490 (Sigma Aldrich, 
St. Louis, MO), a JAK/STAT inhibitor, for 4 hours and/or 1ng/mL recombinant human 
IFN-γ (Calbiochem, Billerica, MA) for 2 hours. Cell lysates were harvested and subjected 
to dual luciferase assay (Promega, Madison, WI).  
Chromatin immunoprecipitation (ChIP)  
 BEAS-2B cells were seeded on 10cm dishes overnight and were processed for 
ChIP using a ChIP-IT Express Kit (Active Motif, Carlsbad, CA). Chromatin was 
immunoprecipitated with mouse anti-human phospho-STAT1 monoclonal antibody (Cell 
Signaling, Beverly, MA) or mouse anti-human RNA polymerase II IgG (Active Motif).  
Antibody-bound protein-DNA complexes were recovered using protein G-coated 
magnetic beads, and the DNA was analyzed by PCR. The oligonucleotide primers were 
designed to amplify the -500 to -700 region of the SLPI promoter, which contained a 
STAT1 binding site and were as follows: 5-CCTGAACCCTACTCCAAGCA -3 and 5- 
AGAAAGACACTTGCCCAGGA -3 (forward and reverse 179 bp). 
Wild type (WT) and stat1
-/- 
mice 
 Male wild type (WT) and stat1
-/- 
(KO) mice bred on a 129S6/Sv/Ev background 
were purchased (Taconic Laboratories, Germantown, NY).  Mice were housed in a 
climate controlled animal care facility and given food and water ad libitum. All aspects of 
animal care and experimentation described in this study were conducted according to 
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NIH guidelines and approved by the North Carolina State University IACUC committee. 
Mice were euthanized, lungs were harvested and either flash frozen in liquid nitrogen or 
fixed with formalin for histological evaluation.   
Immunohistochemistry 
 Formalin-fixed lungs were embedded in paraffin, cut into sections, and prepared 
as previously described (197). Slides were incubated with SLPI antibody (Santa Cruz, 
1:200) followed by incubation with a biotin-labeled anti-rabbit antibody, washed, 
incubated with avidin-biotin complex, and washed. The signal was then detected with 
DAB (3, 3’-diaminobenzidine), washed, and evaluated under light microscopy.  
Anti-NE assay using NLF from non-smokers and smokers 
 SLPI activity was measured by examining the ability of SLPI to halt cleavage of 
NE-specific chromogenic substrate (272). Briefly, rhNE (3.5uM) was incubated with 
NLF samples from non-smokers and smokers for 20 minutes. After incubation, NE-
specific chromogenic substrate (MeOSuc-AAPV-pNA, Sigma, 20mM) was mixed into 
each sample and absorbance at 405nm was measured. No inhibitor was used as a positive 
control. Anti-NE activity was determined by comparing anti-NE activity of samples to 
the anti-NE activity of no inhibitor and was expressed as percent activity. 
Statistical analysis 
 Data are presented as mean (±S.E.M.) for normally distributed data. 
Densitometric quantiﬁcation was performed using Multi Gauge analysis software (Fuji 
Film, Tokyo, Japan). Mann-Whitney tests were used to compare SLPI/STAT1 mRNA, 
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secreted SLPI levels, and SLPI activity in samples from non-smokers and smokers. 
Paired student’s t-tests were used to analyze the effects of AG490 and/or IFN-γ on SLPI 
promoter reporter activity. An unpaired Student’s t-test was used to assess differences in 
slpi levels in WT and stat1
-/-
mice. We performed Mann-Whitney test to compare age and 
BMI, column statistics to compare packs per day, and a two-tailed Chi-square test to 
compare gender in non-smokers or gender in smokers. A p≤0.05 was considered to be 
statistically significant. * p≤0.05, ** p≤0.01. 
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2.4 Results 
Nasal epithelial cells (NEC) from smokers have increased SLPI expression in vitro and in 
vivo. 
 Recent data demonstrate that in the airway of smokers have increased SLPI 
expression and secretion, yet the mechanisms mediating this phenomenon remain unclear 
(71, 145). To examine SLPI levels in respiratory epithelial cells from non-smokers and 
smokers, we used an in vitro model of differentiated primary nasal epithelial cells (NEC), 
as previously described (255). Intracellular and extracellular secreted SLPI levels were 
measured in NEC from non-smokers and smokers. Figure 2-1A-C reveal that NEC from 
smokers have increased SLPI mRNA and secreted SLPI protein compared to non-
smokers. These data reveal that, at baseline, NEC from smokers express significantly 
higher levels of SLPI compared to non-smokers. To confirm and expand our in vitro 
findings, we collected nasal lavage fluid (NLF) from non-smokers and smokers and 
analyzed the NLF for SLPI proteins levels by ELISA. Figure 2-1D indicates that SLPI 
levels are significantly higher in NLF from smokers compared to non-smokers. These 
data demonstrate that SLPI mRNA expression and SLPI secretion is increased in the 
nasal mucosa of smokers in vitro and in vivo.  
STAT1 regulates SLPI transcriptional activation and binds to the SLPI promoter.  
 BLAST analyses revealed that the SLPI promoter contains several ISRE-like and 
ISRE sites and specifically contains a STAT1 (AGGGCC) specific binding site, starting 
at position -601 of the SLPI promoter. We hypothesized that STAT1 could activate SLPI 
expression since the SLPI promoter contains interferon sensitive response elements 
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(ISRE) and ISRE-like sites (310). Exposure of BEAS2-B cells to IFN-γ increased SLPI 
transcription, while treatment with AG490, a JAK/STAT signaling inhibitor, decreased 
SLPI transcriptional activation (Figure 2-2A and B). Transfected cells pre-treated with 
AG490 and exposed to IFN-γ resulted in significantly lower SLPI promoter activation, 
despite IFN-γ exposure (Figure 2-2C). Using chromatin immunoprecipitation (ChIP) 
assays, we confirmed phospho-STAT1 binding to the SLPI promoter utilizing 
oligonucleotide primers that amplified the -500 to -700 region of the SLPI promoter, 
which contained a STAT1 binding site (Figure 2-2D). These data mechanistically 
confirm that STAT1 regulates SLPI transcriptional activation in bronchial epithelial cells. 
stat1
-/- 
mice have decreased SLPI protein expression.  
 Because we show that STAT1 bind to the SLPI promoter, we wanted to further 
elucidate the significance of this association in vivo. To do so, lungs from 129S6/SvEv 
(WT) and stat1
-/-
 mice were analyzed by immunohistochemisitry for SLPI expression. As 
expected, slpi expression was robust in epithelial cells lining the airways of WT mice. 
slpi expression was lower in the lungs from stat1
-/-
 mice compared to WT mice (Figure 
2-3A). Additionally, lung tissue from WT and stat1
-/- 
mice was homogenized and assayed 
for slpi protein levels, using Western blotting. Lung homogenate from stat1
-/-
 mice had 
significantly less slpi protein compared to WT mice (Figure 2-3B and C). These data 
suggest that stat1 regulates slpi levels in the respiratory epithelium in vivo. 
Nasal epithelial cells (NEC) from smokers have increased STAT1 mRNA and protein 
levels.  
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 Although elevated STAT1 has not been reported in smokers, downstream STAT1 
dependent genes such NOS2 are induced in smokers (312). Additionally, there is a 
positive correlation between STAT1 levels and patients with COPD, indicating that 
STAT1 expression and activation may be elevated in smokers (311). To examine 
smoking-induced changes in STAT1 expression, mRNA and protein were harvested and 
analyzed for STAT1 mRNA and protein expression in NEC from non-smokers and 
smokers (Figure 2-4). Our data reveal that, at baseline, NEC from smokers had 
significantly increased STAT1 mRNA and a trend for increased STAT1 protein 
expression compared to non-smokers.  
Extracellular SLPI protein is cleaved in smokers in vitro and in vivo.  
 It has been previously shown that SLPI can be cleaved by serine and cysteine 
protease such as cathepsins, matrix metalloproteinase, chymase, and neutrophil elastase 
(NE) (76, 87, 174, 272). To confirm these studies, we incubated recombinant human 
SLPI (rhSLPI) with and without NE and examined SLPI cleavage by Western blotting. 
We chose NE since it is one of the major proteases elevated in the airways of smokers, 
and NE is the main target for the anti-protease activity of SLPI. Figure 2-5A 
demonstrates the cleavage pattern of rhSLPI induced by NE. Since smoking is 
characterized by increased serine and cysteine protease activity, we hypothesized that 
smokers would have increased cleavage of SLPI (72, 215, 216). To test this hypothesis, 
NLF from non-smokers and smokers were collected, examined for SLPI cleavage by 
Western blotting, and analyzed using densitometry. Figure 2-5B and C demonstrate that 
there is a trend for increased baseline SLPI cleavage in smokers These data imply that 
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although SLPI expression and secretion is higher in smokers, SLPI activity may be 
altered due to proteolytic cleavage.  
Anti-NE activity of SLPI is maintained despite post-translational cleavage of SLPI in 
smokers.  
 Based on our data showing that SLPI is cleaved in smokers and previous studies 
demonstrating that SLPI cleavage alters SLPI functional activity, we hypothesized that 
the functional activity of SLPI may be altered in smokers. We chose to examine SLPI 
function by evaluating the ability of SLPI to inhibit NE, its main target (314, 315).  To 
assess total anti-NE capacity, equal NLF volumes from non-smokers and smokers were 
incubated with recombinant (rhNE) and a NE-specific chromogenic substrate (MeOSuc-
AAPV-pNA 20mM). Figure 2-6 indicates that the increased levels of SLPI seen in 
smokers were functionally active against NE, despite proteolytic cleavage and processing 
that was seen in Figure 2-5.  Additionally, when the percent activity is normalized to 
respective SLPI levels, the anti-NE activity remains greater in NLF from smokers (data 
not shown).  We believe it is not possible to conclude that the anti-NE activity in the 
smokers is due to more SLPI levels or more functionally active SLPI in the NLF. 
However, we are able to conclude that the SLPI cleavage seen in NLF from smokers does 
not impact anti-NE activity. 
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2.5 Discussion 
 Using in vitro and in vivo models, we compared the expression of SLPI in the 
nasal mucosa of non-smokers and smokers, examined the transcriptional regulation of 
SLPI by STAT1, and evaluated the extracellular processing and activity of SLPI in non-
smokers and smokers. Several reports have detailed increased SLPI secretion in smoking-
related lung diseases such as COPD, yet the mechanisms mediating this effect remain 
unclear (71, 145, 309). We confirm these findings by showing increased SLPI mRNA 
and protein secretion in NEC and NLF from smokers (Figure 2-1). We and others had 
previously reported that SLPI expression is regulated by a variety of transcription factors 
such as AP-1, NF-κB, Nrf2 (156, 255). Previous reports and BLAST analysis of the SLPI 
promoter indicate that there are multiple ISRE and ISRE-like sites located on SLPI 
promoter, suggesting STAT1-dependent regulation of SLPI expression (310, 316). Our 
data indicate that in the nasal mucosa of smokers, enhanced baseline expression of 
STAT1 mediates increased SLPI expression. 
 In our study, we observed elevated STAT1 mRNA and protein expression at 
baseline in NEC from smokers (Figure 2-4). While we could not examine phosphorylated 
(activated) STAT1 in NEC from non-smokers or smokers at baseline (data not shown), 
we believe that that downstream SLPI activation is indicative of STAT1 activity. We 
speculate that increased baseline STAT1 expression is independent of external type I or 
type II IFN stimuli, the primary inducers for STAT1, since it has been shown that 
smokers have decreased levels of type I and type II IFN and epithelial cells are not a 
major source for type II IFN (317). As such, we hypothesize that STAT1 may be 
regulated by cigarette smoke-induced modifications to the epithelium. We have 
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previously shown that epigenetic modifications regulate expression of genes in NEC 
from smokers. More specifically, we demonstrated that STAT6, a mediator involved in 
STAT signaling, is hypo-methylated and expressed at higher levels in NEC from smokers 
(194, 318). 
  It is also possible that increased STAT1 may act as a compensatory protective 
mechanism in the epithelium. It has been previously reported that STAT1 acts as a tumor 
suppressor in a variety of capacities (319). The anti-tumor role of STAT1 is further 
supported by the report that STAT1 activation is repressed by microRNAs in cancer cells 
(320). Lastly, it has been previously shown that STAT1 is protective in pulmonary 
fibrogenesis after bleomycin treatment in mice (321). Thus, STAT1, by up-regulating 
SLPI expression, may serve as a compensatory mediator to ameliorate the damaging 
effects of cigarette smoke. Together, these studies may suggest that there are alternative 
mechanisms and functions which regulate STAT1 activation.  
 The link between cigarette smoke and STAT1 activation is unclear and various 
studies have provided conflicting data as to the mechanisms for STAT1 activation in the 
context of cigarette smoke exposure. Although elevated STAT1 has not been reported in 
NEC from smokers, STAT1 levels are correlated with COPD diagnosis and downstream 
STAT1-dependent genes such as NOS2 are induced in smokers (311, 312). Additionally, 
studies performed in bronchial epithelial cell lines have shown that pre-treatment with 
cigarette smoke extract (CSE) reduces STAT1 activation, while other studies report CSE 
treatment increased STAT1 activation (322, 323). It should be noted that for these 
studies, the acute effects of CSE rather than the chronic effects of cigarette smoking on 
the respiratory epithelium after multiple years, or possible decades, of smoking, were 
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examined. Moreover, various groups have reported that nicotine enhances STAT1 
activation, and since nicotine is a main component of cigarettes, this may be an 
alternative explanation for increased STAT1 levels in smokers (324, 325). Additionally, 
it has been shown that STAT1 is strongly induced by reactive oxygen species (ROS) such 
as H2O2. This could alternatively explain a mechanism for ROS-dependent STAT1 
induction since H2O is generated after cigarette smoke exposure (326). Taken together, 
these data may indicate that elevated baseline STAT1 may serve as a response to chronic 
oxidative stress (Figure 2-2 and Figure 2-3).   
 Though we detail the intracellular mechanism for SLPI regulation, we maintain 
that testing the extracellular functional activity of SLPI is important since patients with 
COPD with secondary bacterial infection or cystic fibrosis have increased levels of 
cleaved SLPI, which has been speculated as a main mechanism for inactivation of SLPI 
(72, 145, 173, 272). Extracellular SLPI can be cleaved by respiratory proteases such as 
cathepsin L, matrix metalloproteinase 12 (MMP12), and neutrophil elastase (NE) and can 
serve as a biomarker for airway disease (76, 87, 173, 174, 327). It has been shown that 
cathepsins and MMPs are induced in smokers as well as in chronic cigarette smoke 
exposure models (216, 328). Additionally, alternatively processed SLPI has been shown 
to induce IL-8 and recruit neutrophils leading to enhanced pathophysiology that is 
associated with smoking (172). Since increased protease levels and activity are associated 
with smoking, this could explain the phenomenon of decreased SLPI activity in smokers 
(72, 215, 216). However, we show that although extracellular SLPI is cleaved, the 
functional activity against NE of SLPI is maintained in smokers (Figure 2-5 and Figure 
2-6).  
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 While the major role of SLPI is to inhibit the activity of NE, additional functions 
of SLPI are being discovered. For example, SLPI exerts cellular anti-inflammatory 
effects by preventing the degradation of regulatory components of the NF-κB pathway 
such as IκBα and IκBβ (155). SLPI further suppresses inflammation by directly 
competing for NF-κB binding sites in the promoter regions of pro-inflammatory 
cytokines such as IL-8 and TNF-α (156, 157). SLPI is also protective in the context of 
fungal, bacterial, and viral infections (166, 171, 175, 329, 330). In the context of the 
respiratory mucosa, SLPI has been shown to prevent the proposed proteases in influenza 
A virus (IAV) activation and infection, demonstrating another alternative action of SLPI 
(303, 331). Thus, although anti-NE activity of SLPI is elevated in smokers, secreted SLPI 
levels in smokers may be altered and non-functional in the context of inflammation or 
infection. This is an important area of study considering that cigarette smoking results in 
pro-inflammatory events and impairs anti-IAV response both in vitro and in vivo (194, 
195, 197). 
 Each year, cigarette smoking results in significant loss due to healthcare and 
associated costs (306). We and others have shown that cigarette smoking modifies 
mucosal host defense, yet the specific mechanisms mediating this effect remain unclear 
(194-197). A hallmark of cigarette smoking is a shift in protease/antiprotease balance, in 
favor of protease expression and activity (72, 215, 216). Although it has been previously 
reported that smokers and COPD patients have increased SLPI secreted levels, we 
believe this study is the first to detail the mechanisms regulating SLPI transcription and to 
characterize the extracellular activity of SLPI in respiratory epithelial cells from smokers 
(71, 145). We demonstrate that STAT1 regulates SLPI transcriptional activation and that 
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while extracellular SLPI is cleaved in smokers, the functional activity of SLPI against NE 
is maintained in smokers. Since the canonical SLPI cleavage site occurs within the anti-
NE active site and anti-NE activity was maintained in smokers, we predict that there is an 
alternative cleavage site within the SLPI protein. Based on our data and previous reports, 
these alternative cleavage products could dramatically impact the alternative functions of 
SLPI (76, 332). Detailing alternative extracellular processing and alternative activity of 
SLPI could be of extreme importance since SLPI possesses anti-inflammatory, anti-
bacterial, anti-fungal, and anti-viral properties. Lastly, since the protease/antiprotease 
balance is found in a variety of organs, understanding the regulation and activity of SLPI 
could have significant implications beyond the respiratory mucosa. 
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Table 2-1. Subject characteristics and smoking status. 
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Figure 2-1. SLPI mRNA and protein secretion from in vitro and in vivo samples. 
A) SLPI mRNA expression was examined by qRT-PCR and normalized to 
β-actin mRNA levels in nasal epithelial cells (NEC) from nonsmokers (NS) 
and smokers (SM). B and C) Apical washes from NEC from NS and SM were 
normalized to total protein, examined for SLPI protein levels by Western blot, 
and analyzed by densitometry. D) Nasal lavage fluid from NS and SM 
was used to measure secreted SLPI protein by ELISA. n=5–7 NS and SM. 
*P≤ 0.05, **P≤ 0.01. 
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Figure 2-2. Transcriptional regulation of SLPI in bronchial epithelial cells.  
A) BEAS-2B cells were transfected with an SLPI promoter reporter construct, 
treated with vehicle or IFN-γ for 4 h and assayed for SLPI transcriptional 
activation by luciferase assay. Data were normalized to Renilla levels and 
expressed as relative luciferase units (RLU). After transfection with the SLPI 
promoter reporter construct, cells were treated with vehicle or AG490 for 4 h 
B), or vehicle or AG490 for 4 h C) prior to stimulation with IFN for 2 h, and 
assayed as in A). D) BEAS-2B cells were processed for chromatin immunoprecipitation 
using a phospho-STAT1 antibody. PCR was performed using 
SLPI primers designed to include the STAT1 binding site located on the SLPI 
promoter. Data are representative of 3 independent experiments. *P≤ 0.05 
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Figure 2-3. Expression of slpi in wild-type (WT) and stat1
-/- 
mice. 
A) Lungs from129S6/SvEv (WT) and stat1
-/- 
mice were harvested, fixed, and analyzed for 
slpi protein by immunohistochemistry. B and C) Lungs from WT and stat1
-/-
 
mice were harvested, flash-frozen, and assayed for SLPI protein expression by 
Western blot and analyzed by densitometry. Data are representative of 2 
independent experiments. n= 6 WT and stat1
-/-
mice. **P≤ 0.01. 
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Figure 2-4. STAT1 mRNA and protein levels in NEC from NS and SM.  
A) STAT1mRNA expression was examined by qRT-PCR and normalized to β-actin 
levels in NEC from NS and SM. B and C) Intracellular STAT1 protein levels 
were examined by Western blot and analyzed by densitometry in NEC from 
NS and SM. n= 5 NS and SM. *P≤ 0.05. 
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Figure 2-5. Extracellular posttranslational modification of SLPI.  
A) rhSLPI was incubated with NE for 30 min and examined for SLPI cleavage by 
Western blot. B and C) NLF from NS and SM were analyzed for SLPI cleavage 
products by Western blot and analyzed by densitometry.  n=6–7 NS and SM. 
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Figure 2-6. SLPI activity against NE in NLF.  
NE was incubated with NLF from NS and SM for 20 min. After incubation, NE-specific 
chromogenic substrate was added and absorbance was measured. Data were 
normalized to the activity of no inhibitor and expressed as percent activity. n= 
7 NS and SM. *P≤0.05 
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CHAPTER 3  
Secretory leukocyte protease inhibitor (SLPI) is a novel biomarker for influenza 
replication and infection in the nasal mucosa
†
 
3.1 Overview 
 The respiratory epithelium is the main target for respiratory viruses, including 
influenza virus. Despite large-scale vaccination programs and the development of anti-
viral therapeutics, influenza-associated morbidity and mortality rates have not changed in 
recent years. One important susceptibility factor involved in influenza pathogenesis is the 
protease/antiprotease balance because influenza requires proteolytic cleavage of its 
envelope protein, hemagglutinin (HA), by respiratory serine proteases for productive 
infection. Antiproteases such as secretory leukocyte protease inhibitor (SLPI) inhibit 
serine protease function, decrease inflammatory cascades, and block viral infection. 
Using a bronchial epithelial cell line and primary nasal epithelial cells (NEC), we 
determined that SLPI mRNA is induced during influenza infection and that treating NEC 
with exogenous SLPI during influenza infection decreased viral replication and infection 
in vitro. Additionally, we found that altering SLPI levels, either by exogenous SLPI 
treatment or shRNA, modulated RIG-I mRNA expression, a key pattern recognition 
receptor involved in influenza detection. Moreover, we found that decreasing SLPI 
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expression using shRNA increased influenza replication in vitro, which was mediated by 
enhancing influenza virus entry into target epithelial cells. Finally, we examined the 
association between nasal SLPI levels and markers of live-attenuated influenza virus 
replication in human nasal secretions. Our in vivo clinical data revealed that elevated 
SLPI levels are correlated with decreased markers of influenza replication. These data 
identify SLPI as a novel biomarker associated with susceptibility to influenza virus entry, 
replication, and infection.  
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3.2 Introduction 
 Each year, 2-5 million people worldwide are infected with influenza virus. In the 
US alone, over 20,000 deaths occur due to influenza infection and related complications 
each year (182). Influenza continues to be a public health problem due to high rates of 
viral mutations and reassortment that take place each year as well as a wide range of host 
factors that contribute to influenza susceptibility. We and others have shown that age, 
pre-exiting lung disorders, oxidant exposure, and nutrition status are important factors 
that contribute to influenza pathogenesis, yet the specific mechanism(s) for  enhanced 
influenza susceptibility still remain unclear (195, 197, 262, 333, 334). 
 Intracellular respiratory epithelial cell-derived responses are important factors that 
determine influenza susceptibility since respiratory epithelial cells are the primary targets 
for influenza virus and serve as central orchestrators to initiate an immune response 
against viral infection. Upon infection, epithelial pattern recognition receptors (PRRs), 
which recognize conserved microbial motifs, are induced (17). Respiratory epithelial 
cells possess a wide variety PRRs such as retinoic acid-inducible gene I (RIG-I) (18). 
Once foreign stimuli are detected, respiratory epithelial cells can coordinate and 
communicate with neighboring cells and immune cells to mount an immune response 
against influenza (23). 
 Another important epithelial cell-derived response that regulates influenza 
infection involves the protease/antiprotease balance, a delicate interaction of proteins that 
are critical for tissue homeostasis, basic cellular function, and microbial infections. 
Secretory leukocyte protease inhibitor (SLPI) is a one of the most abundant antiproteases 
found in mucosal sites such as the respiratory tract (153, 154). The main function of SLPI 
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is to inhibit serine proteases such as neutrophil elastase (NE), its main target, as well as 
other serine proteases including cathepsin G, elastase, and chymase (153, 154). However, 
SLPI possesses broad antimicrobial effects, which contributes to respiratory host defense 
responses (156, 157). SLPI is comprised of two closely related domains: a cysteine-rich 
whey acid protein C-terminal domain that is responsible for protease inhibition and an N-
terminal domain that is involved in antimicrobial effector mechanisms (150).  
 The N-terminal domain of SLPI possesses extracellular antibacterial activity by 
disrupting Staphylococcus aureus and Escherichia coli membranes (159). Furthermore, 
SLPI has been shown to exert intracellular antibacterial effects by disrupting translation 
of E.coli during bacterial replication (162). SLPI also exerts fungicidal and fungistatic 
activity towards Aspergillus fumigatus and Candida albicans that is also dependent on its 
N-terminal domain (163).  In the context of viral infections, SLPI has been shown to 
inhibit human immunodeficiency virus (HIV) and respiratory viruses. The first anti-viral 
report demonstrated that SLPI inhibits HIV infection in monocytes and T cells in dose 
dependent fashion (164). Further studies revealed that SLPI exerts anti-HIV properties 
not through direct interaction with the virus, but rather through interacting with the target 
host cell (165). Jana et al. demonstrated that SLPI blocked extracellular receptors on 
innate immune cells and inhibited viral replication. Moreover, follow-up studies found 
that despite decreasing viral load, the infectivity of progeny virions remained unaffected, 
suggesting that SLPI inhibits HIV at the early stages of viral infection (166).  
  In the context of an influenza infection, others have speculated that SLPI may 
exert protective effects (169). For influenza to infect cells, the viral membrane protein 
hemagglutinin (HA) must be proteolytically cleaved and activated by respiratory serine 
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proteases (105-107, 191). SLPI has been speculated as the major antiprotease involved in 
inhibition of the HA-activating respiratory serine proteases (169). Follow-up studies have 
revealed that intranasal administration with recombinant SLPI decreased the generation 
of progeny influenza virus compared to vehicle treated mice infected with IAV (170). 
Furthermore, we have shown that recombinant human SLPI (rhSLPI) inhibited IAV 
replication in Madin Canine epithelial cells (MDCK) in vitro (171). Despite these reports, 
it remains unknown how SLPI exerts anti-influenza properties and if these effects are 
relevant to infections in human models.  
  Investigating strategies to block influenza entry and viral replication in the 
respiratory epithelium may serve as a potential approach to protect against influenza 
infection. Understanding the mechanisms involved in SLPI-mediated protection against 
influenza replication is important since influenza requires proteolytic cleavage by 
respiratory serine proteases for infection. Because SLPI inhibits serine proteolytic 
activity and exhibits anti-viral properties, we hypothesize that SLPI is protective during 
influenza infection. Using in vitro approaches, we mechanistically demonstrate that SLPI 
restricts influenza infection by blocking viral entry. Furthermore, we reveal that elevated 
SLPI levels in nasal lavage are correlated with decreased markers of influenza replication 
in the nasal mucosa in vivo. As such, we provide compelling evidence that SLPI regulates 
influenza virus infection and can serve as important biomarker of susceptibility to 
influenza virus infection in humans.    
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3.3 Materials and methods 
Cell cultures and reagents 
 The canine kidney epithelial cell line, MDCK, and the human bronchial epithelial 
cell line, BEAS-2B, were grown as previously described (249, 255). BEAS-2B stable 
cells were generated by transducing BEAS-2B cells with lentiviral vectors encoding 
SLPI-specific shRNA (shSLPI) or scrambled vectors (shGIPZ) (Thermo Scientific, 
Pittsburg, PA),  at multiplicity of infection of 5 and were cultured and expanded for seven 
days. To select for transduced cells, cells were cultured with puromycin for seven days to 
create BEAS-2B stable cell line, which were used for subsequent assays. 
 For in vitro NEC experiments, epithelial cells from healthy volunteers were 
obtained, expanded, and cultured as described by us previously (255) . Briefly, NEC were 
collected by sampling the inferior surface of the turbinate with a Rhino-Probe curette 
(Arlington Scientific, Arlington, TX), which was inserted through a nasoscope. This 
protocol was approved by The UNC Biomedical Institutional Review Board. Primary 
NEC were expanded to passage 2 then plated on collagen-coated filter supports with a 0.4 
μM pore size (Trans-CLR; Costar, Cambridge, MA). Upon confluency, the apical 
medium was removed to establish air liquid interface culture conditions and to promote 
cellular differentiation (171, 249).  NEC experiments were repeated in cells from 6-8 
donors, and data were normalized to mock control to account for inter-subject variability. 
 rhSLPI (1μg/mL; R&D, Minneapolis, MN) was used in NEC infection 
experiments. In the apical compartment, NEC were inoculated either with influenza and 
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rhSLPI or influenza and vehicle control. 1 hour post inoculation, virus and treatment 
were removed and cells were incubated for an additional 24 hours.  
qRT-PCR 
 RNA isolation, first-strand cDNA synthesis, and qRT-PCR were performed and 
analyzed as previously described (176).  We measured and analyzed the influenza matrix 
2 (M2), SLPI, and β-Actin genes, as previously described (176, 335). For the in vivo 
LAIV human study, influenza B HA mRNA levels were measured and analyzed by area 
under the curve (AUC) analyses, as previously described (195). 
Influenza A virus (IAV) stocks 
 Influenza A/California/10/78 (H1N1) and influenza A/Washington/897/90 
(H3N2) were used for in vitro experiments. Viruses were propagated on MDCK cells as 
previously described (335). For in vitro experiments, influenza was used at a multiplicity 
of infection (MOI) of 1 by tittering stock viruses and back-calculating to the appropriate 
MOI.   
SLPI transcriptional activation  
 BEAS-2B cells were seeded overnight and transfected using Lipofectamine® 
(Life Technologies) following manufacturer’s suggestions, as previously reported (255). 
To measure SLPI transcriptional activation, a plasmid containing luciferase E under the 
control of the SLPI promoter, containing 1266 bp of the 5’ regulatory region on the 
porcine SLPI gene, was used as previously detailed (176).  Cells were transfected with 
1μg SLPI-Luc and 500ng Renilla-TK for 24 hours. Cells were infected with influenza 
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A/California/10/78 (H1N1) or influenza A/Washington/897/90 (H3N2) for 4 hours. Cell 
lysates were harvested and subjected to dual luciferase assay according to manufacturer’s 
guidelines (Promega, Madison, WI).  
Western blotting 
 Protein levels were detected using speciﬁc antibodies (Santa Cruz, Dallas, TX) to 
SLPI (1:1,000) or β-actin (1:2,000), as previously described (176).  
Influenza viral titers 
 IAV titers in apical washes from infected NEC were assessed by 50% tissue-
culture infectious dose (TCID50) assay in Madin Darby Canine Kidney (MDCK) cells as 
previously described (335).    
Virus-like particle (VLP) assay 
 Influenza entry was determined using previously published reagents and methods 
(171, 249). Briefly, VLP were constructed by co-transfecting 293T cells for three days 
with the β-lactamase-M1 fusion construct, as well as HA and NA expressing plasmids, 
generously provided by Dr. Aldolfo Garcia-Sastre (336). The VLP-containing 
supernatants were collected by clearing floating cellular debris by centrifugation at 3,000 
rpm for 10 minutes. The VLP were further concentrated by centrifugation at 4,000 rpm 
for 25 minutes using Amicon Ultra 100kDa centrifuge filters (Millipore, Billerica, MA) 
and store at -80 ºC until use. To activate HA-surface protein on VLP, 2ug/mL trypsin was 
incubated with the VLP stock for 30 minutes at 37ºC.  
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 To assess the effect of SLPI on VLP entry, BEAS-2B cells that were stably 
transduced with lentiviral vectors encoding shSLPI or shGIPZ were plated in 96-well 
plates. After 24 hours, cells were washed, VLPs were added, and cells were incubated at 
37ºC for three hours. After incubation, cells were washed two times to removed unbound 
virus and infected cells were detected at 520nm using GeneBLAzer™, according to 
manufacturer’s recommendations (Invitrogen, Carlsbad, CA). Infected cells were 
quantified using the CLARIOstar plate reader (BMG Labtech, Ortenberg, Germany). 
Data were analyzed by subtracting the 520nm values from either shGIPZ and shSLPI 
cells loaded with substrate alone to shGIPZ or shSLPI cells infected with VLPs and 
loaded with substrate. This analysis allowed for us to account for substrate loading and 
evaluate the amount of 520nm emitted after VLP treatment.  
LAIV human study and nasal lavage fluid (NLF) cell collection  
 14 healthy young adults 18-35 years of age were recruited as described previously 
(195). History of asthma, cardiac disease, egg allergy, prior known influenza illness, and 
pregnancy were exclusion criteria. Subjects that received an influenza vaccine with the 
same antigenic formula in the past year were also excluded. Informed consent was 
obtained from all subjects and the protocol was approved by the UNC Biomedical 
Institutional Review Board. Baseline nasal lavage fluid (NLF) was performed and 
collected as previously described (255). After baseline collection of NLF (day 0), a 
standard dose of the live attenuated influenza virus vaccine (LAIV) was administered into 
each nostril according to the manufacturer’s recommendations (MedImmune, Inc., 
Gaithersburg, MD). NLF was collected 1, 2, 3, and 4 days post-LAIV inoculation and 
NLF cells were assessed for markers of viral replication. SLPI protein levels were 
74 
 
determined in baseline NLF (day 0) using commercially available ELISA (R&D) and 
correlated with levels of viral replication as determined by area under the curve (AUC) of 
viral RNA levels, as previously described (195).  
Statistical analysis 
 Data are presented as mean (±S.E.M.) for normally distributed data. Ordinary 
one-way analysis of variance or unpaired t-tests were used to analyze all BEAS-2B cell 
line data. Column statistics or Wilcoxon matched-pairs signed rank tests were used to 
compare human in vitro NEC data.  Linear regression analysis was used to correlate 
baseline NLF SLPI protein (Day 0) with influenza B HA mRNA levels (Day 1-4 
expressed as AUC). GraphPad Prism was used for all statistical calculations other than 
area under the curve, for which SAS software was used. *p≤0.05, ** p≤0.01, *** 
p≤0.001. 
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3.4 Results 
SLPI expression is induced during IAV infection  
 Reports have shown that SLPI inhibits infection of HIV, human papillomavirus 
(HPV), and respiratory viruses (164, 165, 168). Kido et al. first reported that SLPI may 
possess anti-IAV effects by blocking the proteolytic activation of the influenza virion 
(169, 170). Additionally, we have shown that SLPI inhibits IAV infection in MDCK cells 
(171). Despite these reports, whether and how SLPI exerts anti-influenza effects remains 
unknown. To investigate if SLPI is modulated during IAV infection, we infected 
differentiated NEC as well as a bronchial epithelial cell line, BEAS-2B, with H1N1 and 
H3N2. In NEC infected with H3N2, we found that SLPI mRNA levels trended toward 
significance, which was not seen in the H1N1 infected cells (Figure 3-1A).  
 Similarly, SLPI mRNA was induced in BEAS-2B cells infected with H3N2 and 
H1N1compared to mock infected cells (Figure 3-1B). To determine the effects of IAV on 
the transcriptional activation of SLPI, we utilized a luciferase promoter-reporter system. 
BEAS-2B cells were transfected with a SLPI promoter reporter construct and 
subsequently infected with H1N1 and H3N2. The BEAS-2B cells infected with both 
viruses had significantly increased SLPI gene transcriptional activation compared to 
mock infected cells, assessed by luciferase activity (Figure 3-1C). Interestingly, we found 
that SLPI induction may depend on the virus subtype, since we utilized two different IAV 
viruses, and cell type, since we employed differentiated NEC and BEAS-2B. Together, 
these data suggest that IAV infection up-regulates SLPI expression in respiratory 
epithelial cells.  
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Knocking down SLPI expression increases IAV replication  
 Since SLPI expression was modulated by IAV infection, we wanted to examine if 
SLPI expression was important for IAV infection. To test this, we employed lentiviral 
vectors that expressed SLPI-specific short hairpin RNA (shSLPI) or GIPZ control 
(shGIPZ) vectors to decrease SLPI expression in BEAS-2B cells. These cells underwent 
antibiotic selection to create stably transduced cell lines. The SLPI-specific knockdown 
resulted in a significant reduction of both SLPI mRNA and protein (Figure 3-2A and B). 
To examine the effects of SLPI on IAV infection, shGIPZ and shSLPI cells were infected 
with H1N1 and H3N2 and analyzed for M2 mRNA levels, a viral gene used to assess 
viral replication, by real-time PCR. H1N1 and H3N2 M2 mRNA levels were significantly 
enhanced in cells transduced with shSLPI constructs compared to shGIPZ cells, 
suggesting that SLPI regulates H1N1 and H3N2 infection in BEAS-2B cells (Figure 
3-2C).   
Recombinant human SLPI (rhSLPI) treatment of NEC decreases IAV replication 
 We have recently shown that recombinant human SLPI (rhSLPI) treatment 
inhibits IAV replication in MDCK cells (171). Moreover, we present data demonstrating 
that decreasing SLPI levels in epithelial cells increased markers of IAV replication 
(Figure 3-2). As such, we wanted to investigate the effects of adding exogenous rhSLPI 
treatment on IAV replication in differentiated NEC. NEC were treated with rhSLPI upon 
IAV inoculation. At 24 hours post infection, NEC were harvested and analyzed for viral 
replication. We found that rhSLPI treatment during IAV infection significantly decreased  
M2 mRNA levels as well as viral replication, assessed by TCID50 , which was specific to 
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H3N2 only (Figure 3-3A and B). These results confirm and expand the data from Figure 
3-1 and Figure 3-2. Moreover, these findings further support the hypothesis that SLPI 
protects against IAV infection by dampening intracellular viral replication and 
extracellular release of infectious virions, which may be specific to cell type and virus 
subtype.  
SLPI-dependent alterations to viral replication modifies intracellular anti-viral gene 
expression during IAV infection 
 To determine if modifying SLPI levels altered intracellular anti-viral responses, 
we examined RIG-I mRNA expression. RIG-I is a cytosolic sensor that detects 
5’triphosphate uncapped double stranded or single stranded RNA and is significantly 
induced during influenza infection (337).  In the cells stably expressing the shSLPI 
vector, RIG-I expression was significantly enhanced in the H1N1 and H3N2 infected 
cells (Figure 3-4A). These data confirm Figure 3-2, which showed that decreasing SLPI 
expression increased H1N1 and H3N2 replication in shSLPI cells. Moreover, we found 
that rhSLPI treatment upon IAV inoculation only decreased RIG-I expression in the 
H3N2 infected cells (Figure 3-4B). These findings further corroborate our results from 
Figure 3-3, where the addition of exogenous SLPI decreased IAV replication in 
differentiated NEC infected with H3N2.  
SLPI decreases extracellular viral entry into the cell 
 Since SLPI is induced and modulation of SLPI levels affects intracellular anti-
viral responses, viral replication, and release of infectious virions, we wanted to examine 
if SLPI exerts early extracellular anti-viral effects. For productive infection, the influenza 
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virion must bind to cell receptors for entry into target cells. Since SLPI has been shown 
to bind to cellular receptors and block viral entry in the context of an HIV infection, we 
hypothesized that SLPI may inhibit influenza infection by blocking viral entry into the 
cell (338). To determine if SLPI inhibits influenza entry, we utilized an enzymatic virus-
like particle (VLP) assay, as previously described (171, 249).  We employed this assay in 
the stably transduced BEAS2B cells that were expressing the shGIPZ or shSLPI 
constructs. After VLP treatment, cells were loaded with a cell-permeable fluorogenic 
substrate, CCF2-AM. VLPs that entered target cells cleaved the CCF2-AM substrate 
measured at 520nm. Our data demonstrate that knocking down SLPI expression trended 
towards increasing viral entry, compared to control shGIPZ cells, albeit not statistically 
significant (Figure 3-5). In summary, we mechanistically determined that SLPI exerts 
extracellular anti-viral effects by blocking influenza entry.  
Baseline SLPI protein is correlated with lower levels of influenza replication in vivo 
 To expand our in vitro findings and investigate if baseline SLPI levels predict 
susceptibility to influenza replication in vivo, we used administration of the LAIV as a 
model of influenza infection in humans, in vivo, as previously detailed (195). Briefly, 
LAIV is an attenuated, cold-adapted, temperature-sensitive live virus vaccine that is 
delivered into the nasal passages. Upon inoculation, the LAIV replicates only in the nasal 
passage and induces a localized immune response similar to community acquired 
infection, without serious adverse effects (339).  Baseline NLF (day 0) was collected 
from 14 healthy before LAIV administration. Daily NLF cells were collected for four 
days post-LAIV inoculation and assessed for makers of viral replication using qRT-PCR 
followed by analysis of area under the curve (AUC) for each subject. Baseline SLPI 
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protein levels (day 0) in NLF samples were determined by ELISA and correlated with 
influenza B HA mRNA AUC levels using linear regression analysis. Our data show that 
higher SLPI baseline levels were statistically correlated with lower markers of influenza 
replication, indicating that higher baseline levels of SLPI protein in the nasal mucosa may 
restrict influenza replication and infection in vivo (Figure 3-6). Together, these findings 
suggest that SLPI levels in the respiratory mucosa may regulate influenza replication and 
infection by blocking viral entry. 
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3.5 Discussion 
 We have identified an epithelial cell-derived antiprotease that protects against 
influenza entry, replication, and infection. Using tightly-linked in vitro and in vivo 
models, we have implicated a direct role for SLPI in regulating influenza infection. While 
reports have hinted at the protective effects of SLPI against IAV using animal models and 
MDCK cells, our data confirm and expand these findings, providing a mechanistic basis 
for these observations and translating these findings into relevant human models.(169, 
171) Using differentiated NEC and a bronchial epithelial cell line, we demonstrated that 
SLPI is induced during IAV infection (Figure 3-1). Further, our data revealed that 
epithelial-cell derived, extracellular SLPI possesses anti-influenza activity. For example, 
we showed that decreasing SLPI levels, using lentiviral approaches, significantly 
increased markers of IAV replication (Figure 3-2). In addition, exogenous treatment of 
NEC with rhSLPI during IAV inoculation decreased H3N2 replication and release of 
infectious virions (Figure 3-3). 
 Further, we demonstrate that SLPI blocks early stages of influenza infection by 
reducing viral entry. It is widely accepted that for influenza entry into target cells, the 
viral membrane protein HA must be proteolytically cleaved and activated by serine 
proteases. HA resides on the virion as a fusion-inactive precursor (HA0), and upon 
proteolytic cleavage, the generation of fusion-active trimer, comprised of HA1 and HA2 
subunits, occurs. Respiratory serine proteases such as the type II transmembrane serine 
proteases (TTSPs) have been implicated in HA cleavage and enhanced influenza 
infection (105-107, 191).  Furthermore, we previously showed that enhanced expression 
of TTSPs is associated with increased proteolytic cleavage, activation of HA, and entry 
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into target cells (171). However, despite these findings, it remains unknown if there are 
endogenous antiproteases that regulate TTSP function, block HA cleavage, and decrease 
influenza infection.  
 As such, we hypothesize that SLPI exerts anti-influenza effects by blocking TTSP 
activity. We formulated this hypothesis because the main function of SLPI is to inhibit 
proteases, specifically serine proteases such as NE. The antiprotease activity of SLPI is 
housed in the C-terminal domain of SLPI, which is formed by leucine residues (151, 
340). We postulate that this site is critical for TTSP inhibition since Eisenberg et al. 
demonstrated that this C-terminal leucine is the inhibitory site for NE, chymotrypsin, and 
trypsin (151). Although the inhibitory site for TTSP inactivation remains unknown, we 
speculate that the C-terminal leucine, housed in the active site of SLPI, inhibits TTSP 
function due to conserved targets among serine proteases. As such, extracellular SLPI 
may be exerting anti-influenza effects by blocking TTSP function, decreasing proteolytic 
HA activation, and reducing influenza infection. 
 For our influenza infection model, we used H1N1 and H3N2 in our study: H1N1 
is group-1 influenza virus, while H3N2 is a group-2 influenza virus. We found that SLPI 
was induction and protective against H3N2 infection, but not H1N1 infection, in 
differentiated NEC (Figure 3-1 and Figure 3-3). Since we hypothesize that SLPI blocks 
HA activation by TTSPs, and grouping is dependent on the HA structure, we believe that 
our findings support previously published reports that show HA structure dictates both 
TTSP-dependent activation and antiprotease protection (105, 106, 121, 135, 191).  We 
also found that SLPI was transcriptionally induced and protective during both H1N1 and 
H3N2 infection in BEAS-2B cells (Figure 3-1and Figure 3-2).  These findings illustrate 
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the innate differences between differentiated NEC and a bronchial epithelial cell line, and 
suggest that the anti-viral properties of SLPI may differ between cell types. Broadly, our 
findings corroborate the growing body of literature revealing that antiproteases, such as 
SLPI and serpins, have different anti-influenza activity based on influenza subtype (135, 
341). Further, these findings could have significant implications due to the high 
frequency of H3N2 infection in humans.  
 Additionally, we assessed the relationship between SLPI secreted levels and 
markers of influenza replication in samples from healthy, non-smoking individuals 
inoculated with LAIV. Our data demonstrate a negative relationship between baseline 
SLPI protein and influenza replication (Figure 3-6). These findings indicate that elevated 
levels of SLPI are correlated with decreased markers of influenza replication and 
highlight the potential use of respiratory SLPI levels as a biomarker of susceptibility to 
influenza infections. These findings could have relevance to subpopulations that are at an 
increased risk for influenza infection, such as smokers and individuals with emphysema 
and chronic obstructive pulmonary disease (COPD). 
   A major contributor to elevated risk for respiratory infection involves 
modifications to the protease/antiprotease balance. In the healthy lung, proteases maintain 
tissue homeostasis and are regulated by antiproteases. Although the protease/antiprotease 
balance is required for the maintenance of tissue integrity, elevated net protease activity 
has been associated with lung destruction, the development of chronic lung diseases such 
as emphysema and COPD, and increased risk for respiratory infections (71, 72). In 
addition to increased protease burden, antiprotease function can be reduced due to 
extracellular post-translational modifications. It has been previously shown that SLPI is 
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post-translationally cleaved by respiratory proteases, indicating that excessive protease 
activity results in the cleavage and inactivation of SLPI (76, 174). We have recently 
supported these findings showing that SLPI is proteolytically cleaved by respiratory 
proteases in nasal secretions from smokers (176). Furthermore, others have shown that 
extracellular cleavage oxidative exposure significantly diminishes SLPI function (177).    
 As such, SLPI may not be fully functional in the respiratory mucosa of smokers 
or patients with emphysema or COPD due to elevated protease burden or increased 
oxidant exposure. Since chronic lung disorders and oxidant exposures have long been 
associated with increased susceptibility to respiratory infection, SLPI cleavage and/or 
inactivation may be primary reasons for increased susceptibility to infection in these 
subpopulations (342). Thus, developing strategies to restore SLPI function to protect 
against influenza infection could be highly relevant in susceptible populations such as 
patients with COPD and emphysema. SLPI administration has been examined since the 
early 1990s and has been met with mixed results. In short, delivery of aerosolized SLPI 
was sensitive to respiratory protease cleavage in vivo (272). Various groups have 
examined ways to protect SLPI from protease degradation when delivered to the 
respiratory tract. Gibbons et al. encapsulated SLPI in a liposomal carrier, which protected 
SLPI against proteolytic degradation, was storage stable, and prevented inflammatory 
responses in an asthma guinea pig model (343). 
 Additionally, strategies to endogenously induce SLPI expression and secretion 
could pose as an alternative approach to protect against influenza infection in healthy and 
susceptible populations. Our group has shown that in vitro and in vivo supplementation 
with a nutritional antioxidant sulforaphane (SFN) induces SLPI expression and secretion 
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in healthy donors and reduces markers of viral replication in subjects inoculated with 
LAIV (255, 262). These reports identify a mechanism to enhance SLPI secretion and 
function in the respiratory mucosa to protect against respiratory infection. In sum, we 
have identified SLPI as a potent epithelial cell-derived antiprotease that possesses anti-
influenza activity by blocking influenza entry and replication. Further, we corroborated 
these findings in vivo, indicating that respiratory SLPI levels could serve as a potential 
biomarker of susceptibility to influenza infections.  
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A and B) NEC (A, n=7-8) or BEAS-2B cells (A, n=5-6) were mock infected or infected 
with H1N1 or H3N2. 24 hours post infection, cells were harvested and analyzed for SLPI 
mRNA expression by qRT-PCR. (C) BEAS-2B cells were transfected with a SLPI 
promoter reporter construct, mock infected or infected with H1N1 or H3N2 for 4 hours. 
Lysates were assayed for SLPI transcriptional activation by dual luciferase assay. Data 
were normalized to Renilla levels and expressed as relative luciferase units (RLU). Data 
are representative of 3 independent experiments performed in triplicate. *p≤0.05, 
**p≤0.01, **** p≤0.0001. 
 
Figure 3-1. SLPI is induced during H3N2 infection in NEC and during H1N1 and H3N2 
infection in BEAS-2B cells. 
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 (A and B) BEAS-2B cells (A, n=6) were transduced with lentiviral vectors encoding 
SLPI-specific shRNA (shSLPI) or scrambled vectors (shGIPZ) and underwent antibiotic 
selection to create stable shSLPI or shGIPZ cells. Cells were harvested and analyzed for 
SLPI mRNA and protein levels by qRT-PCR or Western blot, respectively.  (C) BEAS-
2B stable cells (B, n=5-6) were mock infected or infected with H1N1 or H3N2 for 24 
hours. Cells were harvested and analyzed for M2 mRNA expression by qRT-PCR. 
*p≤0.05, **p≤0.01, *** p≤0.001. 
 
 
Figure 3-2. Decreasing SLPI expression increases H1N1 and H3N2 infection in BEAS-
2B cells. 
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 (A and B) NEC (n=7-8) were treated with vehicle control or rhSLPI (1μg/mL) during 
mock, H1N1, or H3N2 inoculation. 24 hours post infection, NEC were harvested and 
analyzed for M2 mRNA expression by qRT-PCR or TCID50 by viral titers, respectively. 
*p≤0.05. 
 
 
 
 
 
Figure 3-3. rhSLPI treatment protects against H3N2 replication. 
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(A and B) BEAS-2B (A, n=5-6) NEC (B, n=7-8) and were treated with vehicle control or 
rhSLPI (1μg/mL) during mock, H1N1, or H3N2 inoculation. 24 hours post infection, 
cells were harvested and analyzed for RIG-I mRNA expression by qRT-PCR *p≤0.05, 
**p≤0.01. 
  
Figure 3-4. SLPI modulates RIG-I expression during influenza infection. 
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BEAS2B stable cells were treated with VLP. 3 hours post treatment, cells were loaded 
with CCF2-AM substrate and were analyzed for viral entry by fluorescence at 520nm. 
Data are indicative from 2 independent experiments performed in quadruplicate. 
  
Figure 3-5. Knocking down SLPI expression increases viral entry. 
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Baseline NLF from healthy volunteers (n=14) was collected and analyzed for SLPI 
protein by ELISA. Following baseline NLF collection, volunteers underwent an LAIV 
inoculation protocol and serial NLF was collected 1-3 days post-LAIV inoculation and 
analyzed for HA mRNA expression by qRT-PCR. Baseline SLPI levels and HA mRNA 
AUC levels were correlated and analyzed using linear regression analysis. 
 
 
.  
 
 
 
 
 
Figure 3-6. Elevated baseline SLPI NLF protein levels are correlated with reduced 
markers of IAV replication in vivo. 
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CHAPTER 4  
Nutritional activation of Nrf2 enhances secretory leukoprotease inhibitor in the nasal 
mucosa
‡
 
4.1 Overview 
 Cells lining the respiratory tract are equipped with protective mechanisms that 
dampen the effects of oxidative stress. The transcription factor nuclear factor (erythroid-
derived 2)- like 2 (Nrf2) regulates the expression of detoxifying enzymes and 
antioxidants including NAD(P)H dehydrogenase (quinone)1(NQO1). Recent data 
indicate that Nrf2 also regulates expression of protease inhibitors such as secretory 
leukocyte protease inhibitor (SLPI). Sulforaphane (SFN), an isothiocyanate found in 
cruciferous vegetables, enhances Nrf2-dependent gene expression. Therefore, we 
hypothesized that SFN supplementation induces SLPI secretion in the nasal mucosa in an 
Nrf2 dependent manner. Healthy nonsmoking adults ingested SFN containing broccoli 
                                                 
‡
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Diaz-Sanchez, Terry L. Noah, Ilona Jaspers. Modified version first published in 
Respiratory Medicine. March 2013, Vol. 107, No. 3, p. 472-475. DOI 
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The first version of the paper was submitted to Respiratory Research but was not 
accepted for publication. In this version, I conceptualized and designed the study; 
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2012.  
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shake homogenate (BSH) consisting of 200g of fresh broccoli sprouts daily for 3 
consecutive days. Nasal lavage fluid (NLF), nasal biopsy (NBS), and blood were 
collected before and after BSH ingestion. NBS was analyzed for the expression of Nrf2 
and NQO1 mRNA. NLF was analyzed for SLPI protein levels by ELISA. In follow up in 
vitro experiments, differentiated primary nasal epithelial cells were used to evaluate the 
impact of SFN on the expression and release of SLPI. Epithelial cells transduced with 
Nrf2-specific shRNA were used to examine the regulatory role of Nrf2 on SLPI 
expression. Supplementation with BSH induced Nrf2 and NQO1 mRNA expression in the 
NBS and increased NLF SLPI levels within 24 hours post ingestion (p<0.01). The 
magnitude of BSH induced SLPI induction was inversely related to the baseline SLPI 
levels (p=0.06). SFN supplementation of epithelial cells in vitro significantly enhanced 
SLPI secretion without affecting intracellular SLPI levels, and these effects were 
significantly decreased in cells transduced with Nrf2-specific shRNA. Our data support a 
relationship between nutritional supplementation, Nrf2 induction, and SLPI secretion. In 
addition, we show that these effects are more pronounced in subjects with low baseline 
antioxidant and SLPI expression. Therefore, ingestion of SFN-containing foods has 
therapeutic potential to augment SLPI expression in the nasal mucosa.  
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4.2 Introduction 
 Exposure to environmental insults that cause oxidative stress and cellular damage 
has been associated with the development of disorders including cancer, cardiovascular 
disease, neurodegenerative diseases, and chronic inflammation (204). To combat and 
alleviate exogenous stressors, mammalian cells have evolved sophisticated sensing and 
signaling pathways. Nuclear factor (erythroid-derived 2)- like 2 (Nrf2) is a transcription 
factor involved in a wide variety of processes and functions as a master regulator to 
control damaging oxidative stress through the regulation of phase II antioxidants 
expression, such as NAD(P)H dehydrogenase (quinone)1 (NQO1) (208, 209).  In the 
respiratory system, Nrf2 plays a critical role in maintaining respiratory homeostasis and 
function since  Nrf2 deficient mice have increased lung vascular permeability, 
inflammation, and epithelial cell injury compared to wild type mice (214, 344, 345). Nrf2 
has also been implicated in various respiratory conditions. For example, Nrf2 deficient 
mice are more susceptible to COPD and asthma (214, 261, 345, 346).   Moreover, Nrf2 
deficient mice and cells treated with Nrf2 shRNA reveal that disrupted Nrf2 function 
leads to an increase susceptibility to both bacterial and viral respiratory infections (219, 
249, 347, 348). 
 Therapies to increase Nrf2 activity are currently being explored in the context of a 
number of different respiratory disorders (212, 346, 349-351). Nutritional 
supplementation could provide an attractive strategy to boost host defense and provide 
protection in the context of respiratory disorders. For example, sulforaphane (SFN) is an 
isothiocyanate found in cruciferous vegetables such as broccoli, brussel sprouts, and 
cabbage and is a potent activator of Nrf2, which has been shown to have anticarcinogenic 
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and cytoprotective properties (352, 353). In the context of the respiratory epithelium, 
SFN has been shown to induce Nrf2 levels and exhibit protective effects in airway 
epithelial cells (250, 253). In vivo and in vitro studies have shown that SFN can induce 
phase II antioxidants like NQO1 and inhibit proinflammatory cytokine release and 
cascade without cellular toxicity (250-252, 254).  
 In addition to phase II antioxidants, recent data indicate that Nrf2 controls the 
expression of a secreted mediator, secretory leukoprotease inhibitor (SLPI) (214, 345). 
SLPI is an 11.7kDa heavily disulfide bonded, positively charged protein found highly 
expressed at mucosal surfaces by epithelial cells as well as in other inflammatory cells 
such as neutrophils and macrophages and has been shown to contribute to host defense 
(138, 281). SLPI is an antiprotease that inhibits serine proteases and also possesses potent 
antimicrobial qualities (154, 166, 354, 355). Additionally, SLPI is able to exert cellular 
anti-inflammatory effects by preventing the degradation of regulatory components of the 
NF-κB pathway such as IκBα and IκBβ (155). SLPI further suppresses inflammation by 
directly competing for NF-κB binding sites in the promoter regions of pro-inflammatory 
cytokines such as IL-8 and TNF-α, leading to decreased transcription of these mediators 
(156, 157).  SLPI has been examined in the context of respiratory disorders such as 
COPD and asthma, demonstrating decreased SLPI secretion during COPD exacerbations 
as well as the development of severe asthma in SLPI knockout mice (356, 357).   
 Since SFN has been shown to exhibit protective effects in vivo and in vitro, we 
hypothesized that SFN supplementation would increase the secretion of SLPI in the 
respiratory mucosa. To test the relationship of nutritional supplementation, Nrf2 
induction, and SLPI secretion, we conducted a pilot clinical supplementation study and a 
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confirmatory mechanistic in vitro study. Both studies suggest that SFN supplementation 
is able to induce SLPI secretion in vivo and in vitro in an Nrf2 dependent fashion.  The 
results of this study illuminate the potential impact of nutritional supplementation to 
enhance SLPI secretion in the nasal epithelium. 
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4.3 Materials and methods 
Study subjects and design- in vivo clinical supplementation study 
 Twelve healthy nonsmoking young adults between 18-35 years old were enrolled 
in a prospective, descriptive study measuring the effects of SFN supplementation via 
broccoli shake homogenates (BSH) on nasal expression of Nrf2, phase II antioxidant, and 
SLPI. An outline of the study design is shown in Figure 4-1. The study took place over 
four days. Baseline nasal lavage fluid (NLF), superficial nasal biopsy (NBS) of epithelial 
cells from one nostril, and blood were taken before the first of three daily ingestions of 
BSH. A second NBS of the opposite nostril was taken after the third ingestion. Additional 
NLF samples were collected two hours post ingestion of the second and third BSH dose 
as well as 24 hours after the last ingestion. Subjects were asked to avoid ingestion of 
cruciferous vegetables for one week prior to and during the study. Informed consent was 
obtained from all subjects and the protocol was approved by the UNC Biomedical 
Institutional Review Board.   
BSH preparation- in vivo clinical supplementation study 
 Commercially available Broccosprouts® (Brassica Protection Products LLC) 
were used in the study.  BSH were prepared similar to a previously described formula 
(254). Briefly, 200g Broccosprouts® were homogenized with 4.8oz water and frozen at -
20 degrees Celsius until the morning of the ingestion protocol.    
Measurement of SFN levels in BSH- in vivo clinical supplementation study 
 BSH were thawed and 1mL aliquots were removed from each lot of shake and 
prepared for analysis of sulforaphane content.  Aliquots were centrifuged at 13.2 x 1000 
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rpm for 3 min at 4ºC. 500µL of supernatant was removed and thoroughly mixed with 
50µL of ice cold trifluoroacetic acid.  Samples were centrifuged as before and the 
supernatant was transferred to an autosampler vial for injection onto the LC-MS/MS.  
The methods for LC-MS/MS analysis were performed as previously described (358). 
Briefly, 10µL of sample were separated on a Shimadzu Prominence HPLC (Shimadzu, 
Kyoto, Japan) using a reversed-phase Phenomenex synergi 4 µm hydro RP 80Å 250 x 1.0 
mm HPLC column.  The flow rate was 0.1 mL/min using 0.1% formic acid in water 
(solution A) and 0.1% formic acid in acetonitrile (solution B).  The gradient was as 
follows: 5% B increasing to 30% (7 min), held at 30% (6 min), washed out with 90% B 
(10 min) and re-equilibrated to 5% B (5 min). The LC eluent was sprayed into an API 
triple quad mass spectrometer 3200 (Applied Biosystems, Foster City, CA) by 
electrospray ionization in positive mode.   
Nasal lavage- in vivo clinical supplementation study 
 Nasal lavage was performed as previously described (359). Briefly, 5ml of sterile 
saline was sprayed into each nostril in 100μl repetitive sprays followed by voluntary 
expelling of fluid into a specimen collection cup. Both nostrils were lavaged in this 
manner and the fluid was pooled together. NLF was filtered using a 40μm cell strainer 
(BD Biosciences, San Jose, CA) and the NLF filtrate was centrifuged at 500g for 5 
minutes to remove cells and debris. Cell free NLF supernatants were stored at -80 
degrees Celsius until used in assays. 
Nasal biopsy and RNA isolation- in vivo clinical supplementation study 
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 NBS were obtained using a sterile, plastic nasal curette (Rhino-Pro™, Arlington 
Scientific, Arlington, TX) as described previously (194). Nasal turbinates were sampled 
by gentle curettage of the inferior turbinates using direct vision of an otoscope. After 
acquisition, the curette was placed into TRIzol (Invitrogen, Carlsbad, CA) for RNA 
isolation purposes.  
qRT-PCR- in vivo clinical supplementation study 
 Total RNA was extracted using TRIzol (Invitrogen) according to manufacturer’s 
suggestions. First-strand cDNA synthesis and qRT-PCR were performed as described 
using commercially available primers and probes for β-Actin, Nrf2, and NQO1 
(Inventoried Taqman Gene Expression Assay) from Applied Biosystems (Foster City, 
CA) (239). Nrf2 primers and probe were used as previously described (360). Gene-
specific mRNA levels were normalized to β-Actin mRNA levels. 
SLPI ELISA- in vivo clinical supplementation study 
 NLF was collected as described above and analyzed for SLPI protein using 
commercially available ELISA kits according to manufacturer’s suggestions (R&D, 
Minneapolis, MN). 
Cell culture- in vitro study 
 For the in vitro experiments, healthy non-smoking volunteers separate from those 
enrolled in the BSH clinical supplementation study were recruited. Nasal epithelial cells 
were obtained, expanded, and cultured as described by us previously (194, 249, 361). 
BEAS-2B cells were cultured as previously described (249).  
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shRNA constructs and lentiviral transduction of BEAS-2B- in vitro study 
 Lentiviral vectors expressing Nrf2 shRNA hairpin oligonucleotides were designed 
and produced as described before (249). BEAS-2B were seeded in a 12-well plate and 
infected with lentivirus at multiplicity of infection of 10 to ensure efficient transduction 
(249).  
Transfection and SLPI reporter assay- in vitro study 
 A plasmid containing luciferase E under the control of the SLPI promoter, 
containing 1385 bp of the 5’ regulatory region on the porcine SLPI gene (a generous gift 
from R. Simmen) was used to measure activation of SLPI expression. (313). Previous 
studies have shown that the porcine SLPI gene promoter exhibits the highest homology to 
human SLPI gene promoter sequences (310). BEAS-2B (1.5x10
5
) were transfected with 
1μg SLPI-Luc and 500 ng TK-Renilla for 24 hours using Lipofectamine® (Invitrogen) 
according to the manufacturer’s suggestions. 5 hours prior to harvest, cell were treated 
with 10μM SFN. Cell lysates were harvested and subjected to dual luciferase assay 
(Promega, Madison, WI). Promoter reporter derived luciferase activity was normalized to 
Renilla activity and expressed as relative luciferase units (RLU).   
Western blotting- in vitro study 
 Whole cell lysates were prepared by lysing the cells in radioimmunoprecipitation 
assay buffer containing 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, and protease 
inhibitors (Cocktail Set III; Calbiochem, SanDiego, CA), as well as phosphatase 
inhibitors (0.5 mM NaVO4and 1 mM β -glycerophosphate). Apical washes were prepared 
by washing the apical surface of differentiated nasal epithelial cells with HBSS.  Whole 
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cell lysate and apical wash (20μg) was separated by 15% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose 
(Schleicher & Schuell Biosciences, Keene, NH). Proteins were detected using speciﬁc 
antibodies to SLPI (1:1,000, Santa Cruz Biotechnology, Santa Cruz, CA), or β-actin 
(1:2,000, US Biological, Swampscott, MA), which served  as a loading control. Antigen-
antibody complexes were incubated with anti-rabbit or anti-mouse, horseradish 
peroxidase -conjugated antibody (1:2000, Santa Cruz Biotechnology) and SuperSignal 
West Pico Chemiluminescent Substrate (Pierce, Rockford, IL).  
Statistical analysis 
 Data were normalized to baseline values and expressed as fold induction over 
baseline.  To determine statistical significance, Wilcoxon signed-rank test was used, 
comparing the column medians to a set value of 1. To evaluate the statistical relationships 
between baseline and responsiveness, linear regression followed by Pearson correlation 
were used. In vitro data were expressed as treatment over vehicle. Student’s t tests were 
used to analyze the effects of SFN on SLPI promoter reporter activity. * p<0.05, ** 
p<0.01, ***p<0.001.  
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4.4 Results 
Subject characteristics and study side effects 
 Table 4-1 details the age, gender, BMI, and ethnicity of enrolled subjects. The 
average age of subjects was 24.8 ± 3.5. Table 4-2 includes a summary of the recorded 
symptoms from the food diaries collected during the study. The most common symptoms 
were increased flatulence and abdominal bloating.  No serious adverse events occurred 
among subjects completing the study. 
SFN levels in BSH  
 To determine SFN levels in BSH, 1mL aliquots were analyzed for free SFN 
levels. BSH samples prepared on two different days, separated by three months, were 
analyzed to assure batch to batch consistency.  Table 4-3 demonstrates that BSH prepared 
on two different dates using different batches of commercially available Broccosprouts® 
had similar free SFN levels.  
BSH supplementation stimulates Nrf2 and phase II antixoidant expression in nasal 
biopsies 
 We evaluated Nrf2 and Nrf2-dependent gene expression in nasal biopsies using 
qRT-PCR. The effects of BSH supplementation in the nasal biopsies were evaluated by 
assessing baseline and post BSH ingestion mRNA levels for Nrf2 and NQO1. BSH 
supplementation appeared to enhance both Nrf2 and NQO1 mRNA expression in some 
subjects but not in others (Figure 4-2). Because of this variability of BSH induced 
changes in mRNA expression, we examined whether baseline expression of Nrf2 and 
NQO1 influenced BSH induced changes in mRNA levels. A significant inverse 
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correlation between baseline values and fold change induction after BSH 
supplementation was seen in nasal biopsies for both Nrf2 and NQO1 mRNA levels 
(Figure 4-2), indicating that subjects with low Nrf2 and NQO1 baseline levels showed 
greater BSH induced mRNA expression changes. 
BSH supplementation induces secreted SLPI levels in nasal lavage fluid  
 In nasal lavage fluid, BSH supplementation stimulated SLPI protein secretion, 
with enhanced SLPI protein levels seen within 24 hours after BSH ingestion (Figure 4-3). 
Similar to the Nrf2 and NQO1 mRNA expression shown in Figure 4-2, there was a trend 
indicating an inverse correlation between baseline and BSH induced SLPI changes 
(Figure 4-3). 
SFN supplementation alters secreted SLPI protein in primary nasal epithelial cells. 
 To further investigate the link between SFN supplementation and nasal SLPI 
expression, we used an in vitro model of differentiated primary nasal epithelial cells 
(NEC). Based on previous studies, we determined that a concentration of 10μM is 
sufficient to distinguish effects of SFN on Nrf2-dependent gene expression without 
causing cytotoxicity (249). NEC were treated with 10μM SFN and analyzed for 
intracellular and secreted SLPI levels 24 hours post supplementation. Analysis of whole 
cell lysates using Western blot indicated that SFN exposure did not enhance intracellular 
SLPI levels (data not shown). However, secreted SLPI protein levels measured in the 
apical washes were enhanced by SFN supplementation (Figure 4-4), corroborating the in 
vivo data, which showed enhanced SLPI levels in the NLF. 
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SLPI expression is regulated by Nrf2 and can be induced with SFN supplementation in 
vitro.  
 To examine the effects of SFN supplementation on the transcriptional regulation 
of SLPI, we utilized a promoter-reporter assay. BEAS-2B cells that were transfected with 
SLPI promoter reporter construct demonstrated that a five hour 10μM SFN 
supplementation increased SLPI gene transcriptional activation (Figure 4-5) To evaluate 
whether the effects of SFN on SLPI gene expression were dependent on Nrf2, we 
transduced BEAS-2B cells with either lentiviral vectors that expressed Nrf2-specific 
shRNA (LV-Nrf2) or scrambled vectors expressing a nonspecific sequence for use as a 
control (LV-Scr) as previously published (249).  Transduced BEAS-2B cells were 
subsequently transfected with the SLPI promoter-reporter and exposed to 10μM SFN for 
5 hours. Our data demonstrate that knock down of Nrf2 reduces SFN-induced SLPI 
expression.  
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4.5 Discussion 
 Nrf2 is a master regulator and transcription factor that defends against oxidants 
but also protects against respiratory disease by regulating the expression of a wide variety 
of intracellular host defense mediators such as direct antioxidants, enzymes that directly 
inactivate oxidants, damage repair intermediates, and anti-inflammatory cytokines (209, 
211, 362-365). In addition, recent data indicate that Nrf2 also controls the expression of 
secreted antiproteases, such as SLPI (214, 345). Since nutritional supplementation with 
SFN has been shown to induce the expression of Nrf2 as well as phase II antioxidants 
both in vivo and in vitro, we hypothesized that SFN supplementation of human volunteers 
would stimulate SLPI expression in the respiratory mucosa (366, 367). Our study 
provides both in vivo clinical supplementation data and in vitro data suggesting a 
relationship between nutritional supplementation, Nrf2, and enhanced SLPI levels.  
 Similar to previous studies, our data show that SFN supplementation enhances the 
nasal expression of Nrf2 and NQO1 (254). SFN supplementation also increased SLPI 
production in vivo and in vitro. Although Nrf2 has been shown to upregulate SLPI 
expression in various in vitro and mouse models, this is the first study to directly link 
nutritional supplementation, Nrf2, and SLPI production in humans, in vivo (214, 345). 
Specifically, our data provide in vivo and in vitro evidence that nutritional 
supplementation upregulates SLPI secretion in epithelial cells (Figure 4-4 and Figure 
4-5). This finding could have broad implications for various respiratory conditions such 
as COPD, emphysema, and asthma, which are associated with decreased SLPI secretion 
(71, 214, 356, 357, 368).  
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 SLPI impacts host defense through the regulation of unchecked inflammation 
(369). SLPI deficient mice have increased susceptibility to LPS-induced endotoxin shock 
as well as excessive inflammatory responses (154, 354, 355, 370). Moreover, SLPI 
inhibits proteases associated with inflammation and tissue damage such as cathespin G, 
trypsin, and neutrophil elastase (138, 371). In the context of respiratory disorders that 
have excessive inflammation such as COPD and asthma, decreased SLPI expression may 
be a contributing factor to the pathogenesis of these disorders (71, 307, 327, 356). An 
unbiased nutrigenomics study revealed that placing asthmatics on a low antioxidant diet 
increased neutrophilic inflammation and worsened asthmatic symptoms (372). Moreover, 
these authors found that genes involved in host defense such as antioxidants and SLPI 
were down regulated (372). Therefore, SFN supplementation could be employed to 
regulate inflammation and restore pulmonary homeostasis through the induction of SLPI. 
 In addition to host defense, SLPI has immunomodulatory capabilities during 
oxidant stress associated conditions such as infection (138, 165, 166, 330, 373-375). For 
example, SLPI has been shown to have anti-influenza A virus (IAV) activity by 
inhibiting the proposed proteases that are involved in IAV activation and infection (106, 
189). We recently have shown that exposing nasal epithelial cells to oxidative conditions, 
such as ozone, decreased SLPI levels, which was associated with increased IAV infection 
(171). Similarly, respiratory diseases, such as asthma, that are known to be associated 
with reduced SLPI levels, are also linked to enhanced susceptibility to IAV. A recent 
study examining the infection rates during the 2009 H1N1 pandemic revealed asthmatic 
children were infected almost twice as often compared to other respiratory viruses (376). 
However, whether reduced levels of antiproteases, such as SLPI, mediate this enhanced 
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susceptibility is not clear. Since decreased levels of SLPI have been examined in the 
context of respiratory disorders, such as asthma, identifying mechanisms to restore SLPI 
could lead to protection from respiratory infection in these subjects. Our study provides 
preliminary evidence that nutritional supplementation could enhance protective host 
defense mechanisms such as inducing SLPI secretion which, in the context of respiratory 
disorders and/or infection, could be protective. 
 Our results also indicate an inverse relationship between baseline and BSH 
induced Nrf2, NQO1, and SLPI levels. Epidemiological studies evaluating the effects of 
multivitamin supplementation show that the changes in serum concentrations of vitamin 
A, C, and E  as well as glutathione reductase activation, were higher in subjects with 
lower nutritional baselines, indicating a dependency on baseline status (377, 378).  
Assessing the baseline antioxidant status of the individual could be especially relevant for 
populations that are targeted with nutritional intervention. Analysis of the National 
Health and Nutrition Examination Survey (NHANES) database shows that in smokers 
and second hand smoke exposed populations, serum antioxidant status and antioxidant 
intake is lower, while markers of oxidative stress are higher (379-381). Furthermore, 
since smokers and individuals with smoking related diseases like COPD are more 
susceptible to respiratory infections, enhancing the secretion of SLPI by ingesting Nrf2 
stimulating supplements could serve as potential clinical therapies to counterbalance the 
oxidative environment and enhance host defense. Additional investigation of the effects 
of nutritional antioxidant supplementation in these populations is warranted. 
 In the respiratory mucosa, SLPI expression is regulated by three transcriptional 
control regions that are responsible for localized SLPI secretion (382). In addition, there 
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are several antioxidant response element (ARE) consensus like sequences [GenBank 
AF205374] in the 1.2kb promoter region of the SLPI gene which led us to  speculate that 
SLPI expression would be regulated though the direct binding of Nrf2 to ARE consensus 
sequences on the SLPI promoter (214, 345).  Data presented here offer in vitro evidence 
demonstrating that knocking down Nrf2 expression reduces SFN induced transcriptional 
activation of SLPI expression in bronchial epithelial cells (Figure 4-5), therefore 
providing a link between nutritional supplementation, Nrf2, and SLPI expression.  
 Our study provides both in vivo and in vitro evidence linking SFN 
supplementation with enhanced SLPI secretion in the nasal mucosa. Together with our 
recent observation demonstrating that SLPI protects against IAV in nasal epithelial cells, 
these data demonstrate the potential role of nutritional supplementation to improve 
respiratory host defense.  We speculate that this may be especially important in the 
setting of chronic respiratory conditions like asthma, COPD, and emphysema (171).  
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Table 4-1. Subject characteristics. 
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Table 4-2. BSH-associated side effects. 
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Table 4-3. SFN levels in BSH.  
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Figure 4-1. Study design.  
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Figure 4-2. BSH supplementation stimulates Nrf2 and phase II antioxidant mRNA 
expression in nasal biopsies.  
NBS obtained at baseline (day 0) or day 2 were analyzed for the expression of Nrf2 
(A+C) or NQO1 (B+D).  A and B) BSH-induced expression of Nrf2 (A) and NQO1 (B) 
were normalized β-actin mRNA levels and expressed as fold induction over baseline. C 
and D) BSH-induced fold induction of Nrf2 C) and NQO1 D) mRNA levels were 
compared to baseline expression for each gene and analyzed by linear regression.   
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Figure 4-3. BSH supplementation induces secreted SLPI levels in NLF.  
A) NLF obtained on days 1-3 was analyzed for SLPI levels and data were normalized to 
baseline SLPI levels for each subject. B) BSH-induced SLPI levels in NLF obtained on 
day 2 were compared baseline levels for each subject and analyzed by linear regression. 
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Figure 4-4. SFN supplementation alters secreted SLPI protein in differentiated NEC.  
NEC were treated with vehicle or 10μM SFN for 24h. At 24h post SFN supplementation, 
apical washes from NEC were harvested and evaluated for SLPI protein levels. A) 
Representative Western blot of SLPI levels in apical washes from NEC treated with 
vehicle of SFN. B) Densitometric analysis of SLPI expression in apical washes of NEC 
treated with SFN and normalized to levels in vehicle treated cells from n=5 different 
experiments.  
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Figure 4-5. SLPI expression is regulated by Nrf2 and can be induced with SFN 
supplementation in vitro.  
BEAS-2B cells were transfected with SLPI-reporter plasmid, exposed to 10μM SFN for 5 
hours, and evaluated for SLPI gene transcription. SLPI-promoter reporter dependent 
luciferase activity was normalized to Renilla levels and expressed as relative 
luminescence units (RLU). In some experiments, BEAS-2B cells were transduced with 
lentiviral vectors encoding Nrf2-specific shRNA (LV-Nrf2) or scrambled vectors (LV-
Scr) 48 hours prior to transfection with SLPI-reporter plasmid and exposed to 10μM SFN 
for 5 hours to evaluate SLPI induction. 
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CHAPTER 5  
TMPRSS2 levels are elevated in the nasal mucosa of smokers, which can be reduced with 
sulforaphane to protect against influenza A virus infection
§
 
5.1 Overview 
 Smokers are more susceptible to respiratory infections such as influenza, yet the 
mechanisms mediating this effect remain unknown. For influenza to infect cells, the viral 
envelope protein, hemagglutinin (HA) must be cleaved by serine proteases for productive 
infection. Type II transmembrane serine proteases such as transmembrane protease serine 
2 (TMPRSS2) have been implicated in HA cleavage and influenza infection. As such, 
investigating strategies to reduce TMPRSS2-dependent influenza activation may be a 
potential strategy to prevent influenza infection. Recent reports indicate that TMPRSS2 
expression and activity can be reduced with the treatment of a nutritional antioxidant 
sulforaphane (SFN). Our data revealed that nasal secretions from smokers increased HA 
cleavage and influenza replication. Moreover, we found that TMPRSS2 levels were 
elevated in the nasal mucosa of smokers. Finally, we determined that SFN treatment of 
nasal epithelial cells decreased TMPRSS2 levels and protected against influenza 
replication. These findings demonstrate that TMPRSS2 is elevated in the nasal mucosa of 
smokers and that SFN supplementation may be an attractive, low-cost strategy to protect 
against influenza infection in susceptible populations such as smokers.   
                                                 
§
 Megan Meyer, Luisa Brighton, Ilona Jaspers.  
 
I conceptualized and designed the study; performed experiments; analyzed and 
interpreted data for all four figures in the paper. I wrote the first draft of the paper.  
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5.2 Introduction 
 In the United States, over 42 million people smoke cigarettes, and each year 
cigarette smoking results in over $100 billion lost to cover healthcare and indirect costs 
(306). Cigarette smoke exposure is a risk factor for cancer, infection, pulmonary disease, 
and susceptibility to respiratory infection (195, 199, 383). Large epidemiological studies 
have shown that after the 1968 influenza Hong Kong epidemic, heavy smokers and light 
smokers had a 21% and a 10% increase in influenza infection, respectively (198). 
Moreover, studies conducted in military bases and in elderly populations have revealed 
that cigarette smoke increases incidences and severity of influenza infection (199, 200).   
 Many groups have investigated the mechanisms underlying the smoking-induced 
risks for influenza infection (200, 218, 384). We have previously shown that smokers 
have dampened innate immune signaling and depressed activation of innate immune cells 
in response to influenza using human in vitro and in vivo models (194-197). Others have 
hypothesized that the smoking-induced risk for increased influenza infection is associated 
with the increased protease burden in the respiratory mucosa of smokers since cigarette 
smoking has long been associated with increased respiratory protease expression and 
activity in vivo (72, 215, 216, 385). Moreover, these findings have been paralleled in 
animal studies. Long-term cigarette smoke exposure in mice, in tandem with respiratory 
syncytial virus infection, resulted in elevated levels of lung inflammation and protease 
expression (217). Additionally, Gualano et al. reported increased protease expression and 
activity in the lungs of cigarette exposed, influenza A virus (IAV) infected mice (218).  
 Increased protease expression and activity is associated with an elevated risk for 
influenza infection due to the structure and function of the viral envelope protein, 
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hemagglutinin (HA). For influenza to infect cells, HA must be proteolytically cleaved 
and activated by respiratory serine proteases. HA resides on the virion as a fusion-
inactive precursor (HA0), and upon proteolytic cleavage, a fusion-active trimer with 
disulfide-linked HA1 and HA2 subunits, is generated (105, 107, 188, 189). After entry 
into the cell, the virion enters endosomal compartments and upon acidification of the 
endosome, the viral and host membranes fuse together. The membrane fusion enables 
viral entry into the cell and initiation of viral replication (190).  
 Proteases such as the type II transmembrane serine proteases (TTSPs) are 
produced and secreted by the respiratory epithelial cells and have been implicated with 
increased viral infection (105-107, 191). TTSPs are comprised of four subfamilies 
including the transmembrane protease serine (TMPRSS) subfamily, which includes 
TMPRSS2 (94). TMPRSS2 possesses a wide range of functions specific to epithelial cell 
biology. TMPRSS2 reduces epithelial sodium channel activity and is associated with the 
development of severe forms of prostate cancer (108, 110, 111). Furthermore, TMPRSS2 
activates respiratory viruses to allow for increased viral infection (117, 118).  Bottcher et 
al. reported that cells stably expressing TMPRSS2 had HA cleavage and elevated IAV 
replication (105, 107). However, despite the role of TMPRSS2 in IAV pathogenesis, it 
remains unknown if TMPRSS2 contributes to IAV infection in susceptible populations, 
such as smokers, and if these effects can be mitigated with novel intervention strategies.  
 Investigating strategies to decrease TMPRSS2 could protect against IAV 
infection. Since smokers are deficient in many necessary vitamins and minerals, one 
strategy could involve nutritional antioxidant supplementation (223). In a national study 
of over 7800 healthy adults including smokers or nonsmokers, Wei et al. found that 
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smokers had lower serum antioxidant levels (224). Moreover, this group identified that 
smokers had significantly lower dietary intakes of vitamins and minerals. These data 
suggest that smokers may suffer from additive bad health habits (i.e. smoking and poor 
nutrition), further increasing their pro-oxidant status and enhancing their risk for 
respiratory infection. 
 Antioxidants are an attractive intervention because antioxidants inhibit oxidative 
stress, a main result of cigarette smoking. One potent antioxidant that decreases oxidative 
stress is sulforaphane (SFN). Found in cruciferous vegetables such as broccoli and 
cabbage, SFN enhances antioxidant responses in human respiratory epithelial cell models 
and in human in vivo SFN supplementation protocols (250-254). Additionally, SFN 
reduces TMPRSS2 expression and activity in prostate cancer cells (259, 260). 
Furthermore, we have shown that SFN blocked IAV replication by halting IAV entry into 
bronchial epithelial cells (249). Our group has recently expanded these findings in vivo, 
showing that sulforaphane-containing broccoli sprouts significantly reduced markers of 
viral replication in smokers (262). These results indicate that SFN may be a safe, low-
cost intervention for decreasing TMPRSS2 expression/secretion and protecting against 
influenza infection in a particularly susceptible population, such as smokers. 
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5.3 Materials and methods 
Differentiated human nasal epithelial cells (NEC)  
 NEC from volunteers were obtained, expanded, and cultured as described by us 
previously (255) . Briefly, NEC were by sampling the inferior surface of the turbinate 
with a Rhino-Probe curette (Arlington Scientific, Arlington, TX), which was inserted 
through a nasoscope. This protocol was approved by The UNC Biomedical Institutional 
Review Board. Primary NEC were expanded to passage 2 then plated on collagen-coated 
filter supports with a 0.4 μM pore size (Trans-CLR; Costar, Cambridge, MA). Upon 
confluency, the apical medium was removed to establish air liquid interface culture 
conditions and to promote cellular differentiation (171, 249). For some experiments, NEC 
were supplemented with SFN (10μM; Sigma Aldrich, St. Louis, MO) as previously 
described (255).   
Human study and sample collection  
 We analyzed samples from previously completed clinical studies that enrolled 
health young adults 18-35 years of age, see previously published studies for subject 
demographics(176, 262). Samples from 8 nonsmokers and 8 smokers were analyzed for 
Figure 5-1 and samples from 40 nonsmokers and 22 smokers were used for Figure 5-2, 
for a total of 48 non-smokers and 30 smokers, see previous publications for subject 
demographics (176, 262). Informed consent was obtained from all subjects and the 
protocol was approved by the UNC Biomedical Institutional Review Board. Nasal lavage 
was performed and collected as previously described (255). All samples were stored at      
-80ºC until analysis.  
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IAV stocks and infection 
 For ex vivo hemagglutinin (HA) cleavage assays, we utilized influenza 
A/Malaya/302/1954 (H1N1), which was obtained from the American Type Culture 
Collection (ATCC, Manassas, VA). To assess secreted protease activity in NLF samples 
from non-smokers and smokers, we used influenza A/Bangkok/1/79 H3N2. Influenza 
A/California/10/78 (H1N1) was used for in vitro NEC experiments. Influenza 
A/Malaya/302/1954 and influenza A/Bangkok/1/79 were propagated in eggs as 
previously described (171, 249, 334). Influenza A/California/10/78 was propagated on 
MDCK cells as previously described (335). For NEC experiments, influenza 
A/California/10/78 was used at a multiplicity of infection of 10.   
Ex vivo influenza HA cleavage by secreted proteases from NEC 
 To investigate the differences between non-smokers and smokers in HA-
activating protease activity, we performed ex vivo influenza HA cleavage assays as 
previously described (171, 386). Briefly, apical washes were collected from NEC from 
non-smokers and smokers (n ≥4) by washing the apical surface of the cells with HBSS. 
Total protein was assessed (Bio-Rad, Hercules, CA) and 50 μg of total protein was 
incubated with influenza A/Malaya/302/1954 H1N1. After incubation, samples were 
subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), 
transferred to nitrocellulose membranes (Bio-Rad), and incubated with an HA-specific 
antibody to assess HA protein levels.  
Western blotting 
122 
 
 All samples were separated by 12% SDS-PAGE and transferred to nitrocellulose. 
Protein levels were detected using speciﬁc antibodies to influenza A virus H1 HA 
(Abcam, Cambridge, MA; 1:500) or TMPRSS2 (Santa Cruz, Dallas, TX; 1:1,000). 
Antigen-antibody complexes were incubated with horseradish peroxidase-conjugated 
secondary antibody and were detected using chemiluminescence. Densitometry was 
performed using a Fujifilm LAS-3000 imager (Fuji Film Global Tokyo, Japan).   
IAV-activating serine protease activity in NLF samples from non-smokers and smokers 
 To determine if the serine proteases present in the NLF can cleave HA to produce 
infectious virions and if this serine protease activity differs between non-smokers (n=8) 
and smokers (n=8), we performed ex vivo IAV-activating protease assays, as previously 
described (171, 386). Briefly, 50 μg NLF was incubated influenza A/Bangkok/1/79 
H3N2. To determine if the secreted serine proteases present are able to facilitate multiple 
rounds of viral replication, we employed a modified titer protocol using Madin-Darby 
canine kidney cells (MDCK). We employed MDCK cells for this assay since MDCK 
require exogenous serine protease addition to support multiple rounds of infection, which 
would be derived from the serine proteases found in NLF. After NLF incubation with 
IAV, samples were diluted for titering on MDCK monolayers. After three days of 
incubation, human erythrocytes were added to each well, and wells considered positive 
for viral replication were analyzed. Viral replication was expressed as log TCID50.  
TMPRSS2 protein levels in NLF 
 NLF from non-smokers (n=32) and smokers (n=14) analyzed for TMPRSS2 
protein using commercially available ELISA (MyBioSource, San Diego, CA).  
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qRT-PCR 
 RNA isolation, first-strand cDNA synthesis, and qRT-PCR were performed and 
analyzed as previously described (176).  To examine markers for influenza replication in 
NEC experiments, primers for influenza A matrix 2 (M2) gene was used, as previously 
described (262). Commercially available primers and probes for TMPRSS2 and β-Actin 
were also employed. (Applied Biosystems, Life Technologies, Carlsbad, CA). Gene-
specific mRNA levels were normalized to β-Actin mRNA levels and analyzed similar to 
previously published methods (176). 
Statistical analysis 
 Data are presented as mean (±SEM) for normally distributed data. Densitometric 
quantiﬁcation was performed using Multi Gauge analysis software (Fuji Film, Tokyo, 
Japan). Mann-Whitney tests were used to compare IAV-activating serine protease 
activity in NLF samples from non-smokers and smokers as well as TMPRSS2 protein 
levels in NLF from non-smokers and smokers. Wilcoxon matched-pairs signed rank tests 
or Sidak’s Two-way analysis of variance were used to compare human in vitro NEC data.  
GraphPad Prism was used for all statistical calculations. *p≤0.05; **p≤0.01. ***p≤0.001 
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5.4 Results 
Nasal secretions from smokers increase HA cleavage and IAV replication  
 We have previously shown that differentiated NEC from smokers have increased 
levels of IAV replication compared to non-smokers, which was attributed to dampened 
intracellular signaling (194). However, we wanted to ascertain if the extracellular, 
secreted factors in NEC from smokers could activate and induce elevated levels of IAV 
infection compared to NEC from non-smokers. To examine HA activation, we collected 
apical washes from NEC from non-smokers and smokers and incubated the washes with 
IAV, which are predominately HA0, for 30 minutes. After incubation, we examined HA 
cleavage by Western blot. Incubating NEC washes from smokers resulted in greater HA 
conversion and cleavage into HA1 and HA2 compared to NEC washes from non-smokers 
(Figure 5-1A).   
 Similar to previously published studies, we wanted to assess whether NLF from 
non-smokers and smokers differ in their ability to produce infectious virions by using a 
modified titer assay, which determine if the secreted proteases present in the NLF can 
facilitate multiple rounds of IAV infection (171, 386). We performed this assay using 
MDCK cells since this cell type requires the addition of an exogenous serine protease, 
such as trypsin, to replicate influenza virus.  NLF from non-smokers and smokers were 
incubated with influenza and added to monolayers of MDCK cells to examine influenza 
replication. Figure 5-1B reveals that NLF from smokers produced infectious IAV virions 
at a significantly higher rate than NLF from non-smokers. Together, these results convey 
that nasal secretions from smokers elevated rates of HA cleavage and enhanced IAV 
replication using in vitro and in vivo samples. 
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TMPRSS2 levels are elevated in NLF from smokers 
 Proteases such as TMPRSS2 have been implicated in the increasing rates of viral 
infection (105-107).  In recent reports, TMPRSS2 has been shown activate and increase 
rates of IAV infection in animal models (119-121).  We and others have shown that that 
asthmatics have increased risk for influenza infection, and we recently showed that 
asthmatics have increased TMPRSS2 levels in nasal secretions (334, 376, 386). As such, 
TMPRSS2 may contribute to the increased HA cleavage and infection seen in asthmatics. 
While there is substantial evidence implicating TMPRSS2 in IAV pathogenesis, there are 
limited investigations examining the effects of TMPRSS2 in the context of cigarette 
smoke. To examine the effects of smoking on TMPRSS2 secretions in vivo, we collected 
NLF from non-smokers and smokers and assayed for TMPRSS2 protein by ELISA. Data 
from Figure 5-2 demonstrate that smokers have increased TMPRSS2 protein NLF levels 
compared to non-smokers.    
SFN treatment decreases TMPRSS2 secretion in vitro  
 Because we identified that TMPRSS2 is elevated in the NLF of smokers, we 
wanted to investigate therapies that could decrease TMPRSS2 expression and secretion 
and protect against IAV infection. We decided to examine the effects of a nutritional 
antioxidant SFN since SFN decreases oxidative stress and protease activity (252, 256-
258, 366, 387). We have previously shown that SFN reduced IAV entry into respiratory 
epithelial cells and that in vivo SFN supplementation decreased markers of influenza 
replication in smokers (249, 262). Interestingly, TMPRSS2 is implicated in the 
development and severity of prostate cancer, and SFN decreases TMPRSS2 expression in 
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prostate cancer cell lines (259, 260, 388, 389). Our data reveal that SFN supplementation 
in NEC significantly reduced TMPRSS2 secretion compared to vehicle treated cells 
(Figure 5-3). This finding indicates that SFN treatment decreased TMPRSS2 secretion in 
primary NEC.  
in vitro SFN treatment decreases TMPRSS2 expression/secretion and decreases markers 
of viral replication during IAV infection  
 Since we demonstrated that SFN decreases TMPRSS2 secretion in NEC, we 
wanted to investigate if SFN reduced TMPRSS2 expression and secretion during an IAV 
infection and if SFN treatment decreased markers of viral replication. To examine the 
impact of SFN treatment on TMPRSS2 expression and secretion, NEC were 
supplemented with vehicle or SFN (similar to Figure 5-3) and infected with IAV for 24 
and 48 hours, with daily vehicle or SFN supplementation. Our results demonstrate that 
SFN supplementation decreased TMPRSS2 mRNA expression 48 hours post IAV 
infection and TMPRSS2 protein secretion 24 hours post infection (Figure 5-4). 
Moreover, SFN reduced markers of viral replication 48 hours post infection, assessed by 
M2 mRNA levels (Figure 5-4). These data reveal that SFN decreased TMPRSS2 
expression and secretion as well as markers of IAV replication after infection.    
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5.5 Discussion 
 It has long been accepted that cigarette smoking increases susceptibility to 
influenza infection (198-200). We have previously shown that smokers have dampened 
intracellular signaling and depressed innate immune cell activation during influenza 
infection, suggesting that inherent intracellular mediators are deficient in smokers (194-
197). However, we hypothesize that secreted mediators from the respiratory epithelium 
infection in smokers alter the influenza virion and enable enhanced rates of influenza 
replication. Specifically, we demonstrated that in vitro washes from NEC from smokers 
induced HA cleavage and in vivo NLF from smokers increased rates of viral replication 
compared samples from non-smokers (Figure 5-1).  
 The elevated protease burden in the respiratory mucosa could be a prominent 
contributor to HA cleavage and influenza infection in smokers, yet few studies have 
examined this hypothesis. We have previously shown that exposure to oxidants, such as 
ozone, increased serine protease activity, HA cleavage, and IAV replication (171). 
Moreover, a recent report demonstrated that the respiratory mucosa of asthmatics 
contained elevated HA-activating protease activity, which correlated with increased rates 
of viral replication (386). As such, we wanted to determine if cigarette smoking induced 
TMPRSS2, a HA-activating serine protease. We found that in vivo NLF from smokers 
had elevated TMPRSS2 protein (Figure 5-2). 
 Since TMPRSS2 is involved in influenza activation and infection, we wanted to 
investigate strategies to decrease TMPRSS2 expression and secretion. TMPRSS2 mRNA 
levels are elevated in prostate cancer cell lines and nearly two-fifths of prostate cancer 
patients express duplication of the TMPRSS2 gene (110, 111). Increased levels of 
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TMPRSS2 in prostate cancer cells are found as a gene fusion product of TMPRSS2 with 
an E-twenty-six (ETS) transcription factor, such as ERG and ETV (112). This fusion 
event generates a C-terminally truncated TMPRSS2 protein attached to an N-terminally 
truncated ERG/ETV protein, which induces migration and invasion in non-tumorigenic 
epithelial prostate cells (113). The TMPRS2-ERG/ETV gene fusion is regulated by 
androgen receptor (AR) signaling and is associated with a high rate of prostate cancer 
recurrence and/or severe disease (114-116).  Thus, identifying mechanisms to decrease 
AR signaling and stability could be ways to decrease TMPRSS2 levels and protect 
against influenza infection. 
 AR signaling and stability can be modulated by SFN, a nutritional antioxidant 
found in cruciferous vegetables, to decrease TMPRSS2 expression (259). A recent report 
from Schultz et al. confirmed and expanded these findings showing that nuclear factor 
(erythroid-derived 2)- like 2 (Nrf2), a key transcription factor induced after oxidative 
stress or SFN supplementation, negatively regulated AR transactivation of TMPRSS2 
(260). Furthermore, the authors found that nuclear factor (erythroid-derived 2)- like 1, a 
cytoplasmic transactivator of AR, was sequestered in the nucleus and could not activate 
AR, when Nrf2 was induced. We corroborate these findings and show that SFN 
supplementation decreased TMPRSS2 secretion in differentiated NEC (Figure 5-3).  
 The SFN-mediated decrease of TMPRSS2 expression and secretion was 
protective in the context of an IAV infection in NEC. We found that treating NEC with 
SFN for 24 hours, infecting with IAV for 24 and 48 hours with daily SFN treatment, 
significantly reduced intracellular TMPRSS2 mRNA and extracellular TMPRSS2 protein 
secretion (Figure 5-4A and B). Moreover, this treatment led to a significant decrease in 
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M2 gene expression (Figure 5-4C). These data indicate a potential role for nutritional 
supplementation with SFN to reduce TMPRSS2 expression and secretion as well as 
influenza replication.   
 Investigating strategies to reduce TMPRSS2 expression and activity could 
broadly protect against various influenza strains and other respiratory viruses. In recent 
reports, TMPRSS2 has been shown to preferentially cleave H1N1, and to a lesser degree, 
H3N2 (119). Recent reports have further expanded on the HA-specificity of TMPRSS2. 
One group demonstrated that TMPRSS2 knockout mice were protected from lethal H1N1 
but not lethal H3N2 infection, while another group showed that TMPRSS2 knockout 
mice were protected against both H1N1 and H3N2 infection (120, 121).  These opposing 
findings suggest that HA activation not only depends on HA structure, but can vary 
amongst different viral strains bearing the same HA subtype. Additionally, TMPRSS2 
has been shown to cleave and activate other respiratory viruses such as metapneumovirus 
and parainfluenza (117, 297). Other reports indicate that TMPRSS2 activates 
coronaviruses such as severe acute respiratory syndrome coronavirus (SARS-CoV) and 
Middle East respiratory syndrome coronavirus (MERS-CoV) (118, 288, 289, 390). Due 
to the high infection rates of metapneumovirus and parainfluenza virus in children as well 
as the emergence and high mortality rate of SARS-CoV and MERS-CoV, identifying 
strategies to reduce TMPRSS2-induced activation of these respiratory viruses could 
lessen the public health burden of these viruses.  
 Furthermore, investigating strategies to decrease respiratory protease expression 
and activity could prevent chronic lung disorders. In the healthy lung, proteases are 
critical regulators of tissue homeostasis. However, increased protease activity contributes 
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to lung destruction and the development of chronic disorders such as emphysema and 
chronic obstructive pulmonary disease (COPD), which has been associated with 
increased susceptibility to influenza infection (71, 72, 342). While we present new data 
demonstrating SFN-mediated decrease of a respiratory serine protease, others have 
shown that SFN inhibits MMP expression using animal models of central nervous system 
injury as well as in breast cancer cell lines (256-258).  As such, SFN supplementation 
could serve as a low-cost and safe therapy to reduce respiratory serine proteases, decrease 
the development of chronic lung disorders, and protect susceptible populations from 
respiratory viral infection.  
 In sum, we provide compelling evidence that the nasal epithelial secretions from 
smokers activated the influenza virion and enhanced rates of influenza replication. 
Moreover, we demonstrated that TMPRSS2 was elevated in the NLF from smokers. 
Additionally, we showed that SFN supplementation reduced TMPRSS2 levels and 
protected against IAV infection. We hypothesize that the SFN-mediated protection 
against IAV was achieved by blocking viral activation and entry. Since there is 
substantial evidence implicating TMPRSS2 in a variety of respiratory viral infections, 
there is large clinical significance to these findings since we identified and elucidated a 
mechanism to reduce TMPRSS2 expression/secretion and TMPRSS2-mediated viral 
infection in differentiated NEC.  
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Figure 5-1. Nasal secretions from smokers increase HA cleavage and IAV replication. 
(A) Apical washes from non-smokers and smokers n≥4 each were harvested, incubated 
with IAV, and analyzed for HA cleavage by Western Blot. (B) NLF from non-smokers 
and smokers (n=8 each) were collected, incubated with IAV, and subjected to viral 
titering.  *p≤0.05. 
.  
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Figure 5-2. TMPRSS2 is elevated in NLF from smokers in vivo. 
NLF from healthy non-smoker (n=32) and smoker (n=14) volunteers was collected and 
analyzed for TMPRSS2 protein via ELISA *p≤0.05.  
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(A and B) NEC (n=7) were supplemented with vehicle or SFN for 24 hours. Apical 
washes were harvested and analyzed for secreted TMPRSS2 protein by Western blot. 
Representative image of Western Blot and densitometric analysis (n=7) of TMPRSS2 
protein secretion. *p≤0.05. 
 
  
Figure 5-3. SFN supplementation in NEC decreases TMPRSS2 expression/secretion in 
vitro. 
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Figure 5-4. SFN supplementation in NEC decreases intracellular TMPRSS2 mRNA, 
extracellular TMPRSS2 protein levels, and markers of IAV replication in vitro. 
(A-C) NEC (n=7) were supplemented with vehicle or SFN for 24 hours and infected with 
H1N1 for 24 and 48 hours, with daily vehicle or SFN supplementation. Cells were 
harvested and analyzed for TMPRSS2 mRNA expression by qRT-PCR and protein 
secretion by Western blot and M2 mRNA by qRT-PCR, respectively.  *p≤0.05; 
***p≤0.001. 
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CHAPTER 6  
Discussion 
6.1 Modifications to the antiprotease shield: implications for infection 
Is secretory leukocyte protease inhibitor (SLPI) functional in the respiratory mucosa of 
smokers? 
 We present evidence showing that cigarette smoking alters components of the 
protease/antiprotease balance (Chapters 2 and 5). These results support the expansive 
literature indicating that smokers and patients with smoking-induced lung diseases have a 
modified respiratory protease/antiprotease balance, in favor for increased protease 
expression and activity (71, 72, 215, 385). Others have shown that SLPI is proteolytically 
cleaved by respiratory proteases such as cathepsins, matrix metalloproteases (MMPs), 
and neutrophil elastase (NE), which alters SLPI function (76, 87, 173, 272). Furthermore, 
work from Cavarra et al. showed that cigarette smoke induces oxidative modifications to 
the tertiary structure of SLPI and significantly diminishes SLPI function (177). We 
support these findings, demonstrating that SLPI is proteolytically cleaved by respiratory 
proteases in nasal secretions from smokers (Chapter 2) (176). Together, these findings 
demonstrate that SLPI may not be fully functional in the respiratory mucosa of smokers 
or patients with emphysema or chronic obstructive pulmonary disease (COPD), which 
may be relevant in the context of a respiratory infection (76, 174).  
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 In chapter 3, we demonstrated that SLPI is protective against influenza infection 
by blocking viral entry into target epithelial cells in vitro and restricting markers of viral 
replication in non-smokers in vivo. These findings are supported in the literature and 
further implicate and expand the anti-viral role of SLPI in influenza pathogenesis (171, 
303, 331). However, it remains unknown if the SLPI present in the nasal secretions of 
smokers possesses anti-influenza activity as seen in chapter 3. To first investigate if total 
secreted SLPI levels are affected by cigarette smoking status, we present preliminary data 
demonstrating that SLPI in nasal lavage fluid (NLF) negatively correlates with urine 
cotinine/creatinine levels, a marker used to assess cigarette smoking, indicating that 
heavier smokers have reduced SLPI in mucosal secretions (Figure 6-1).  
  To determine if SLPI in the NLF from smokers is protective against influenza 
replication, we examined samples from healthy smoking volunteers that were inoculated 
with the live-attenuated influenza vaccine (LAIV), as previously detailed (195). Briefly, 
baseline NLF (day 0) was collected from 11 healthy smokers before LAIV 
administration. Daily NLF cells were collected for four days post-LAIV inoculation and 
assessed for makers of viral replication using qRT-PCR, followed by analysis of area 
under the curve (AUC) for each subject. Baseline SLPI protein levels (day 0) in NLF 
samples were correlated with influenza hemagglutinin (HA) mRNA AUC levels. Of note, 
SLPI levels were quantified by enzyme linked immunosorbent assay, which does not 
distinguish between cleaved and uncleaved SLPI. This is an important distinction since 
we and others have shown that SLPI is proteolytically cleaved by respiratory proteases 
such as cathepsins, MMPs, and NE, which can alter SLPI function (Chapter 2) (76, 87, 
173, 176, 272). Our data show there was no correlation between SLPI and influenza HA 
137 
 
mRNA and indicate that SLPI is not protective in the context of an influenza infection in 
smokers, contrary to what we found in non-smokers (Figure 6-2 and Chapter 3). In sum, 
these data may offer an explanation to the large amount of literature demonstrating that 
smokers are more susceptible to influenza infection (195-197, 199, 200). 
6.2 Targeting the antiprotease shield: mechanisms to prevent infection and/or 
chronic lung disease   
Can recombinant SLPI (rSLPI) be delivered as respiratory therapeutic intervention? 
 We and others demonstrate that in addition to functioning as an antiprotease, 
SLPI possesses broad anti-inflammatory and antimicrobial effects. This indicates that 
delivering SLPI into the respiratory tract may serve as a mechanism to protect against 
lung disease and/or infection. Therapeutic delivery of SLPI has been examined since the 
early 1990s and has been met with mixed results. Administration of a single, aerosolized 
50mg rSLPI dose into the lungs of sheep was found to increase anti-NE activity (391).  
McElvaney et al. examined the effects of aerosolized rSLPI in the context of cystic 
fibrosis, a lung condition characterized by excessive inflammation and protease activity. 
rSLPI treatment decreased active NE, interleukin-8 (IL-8) secretion, and neutrophil count 
(392).  While these findings were extremely promising, these authors also demonstrated 
that rSLPI did not accumulate in the respiratory tract, despite twice daily delivery (393).   
 These observations implied that rSLPI was possibly processed and inactivated by 
respiratory proteases. Indeed, this hypothesis was confirmed by additional groups. 
Weldon et al. demonstrated that SLPI is cleaved and inactivated by serine proteases such 
as NE in the lung secretions of cystic fibrosis patients (272). The authors also 
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demonstrated that NE cleaved rSLPI at two locations on the N-terminal region, which 
decreased the anti-inflammatory properties of SLPI, as measured by the ability of SLPI to 
bind to nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)  promoter 
sites (272). Others have supported these findings (76, 87, 173).  As such, investigating 
strategies to protect SLPI from proteolytic processing and cleavage during in vivo 
instillation may serve as an attractive approach to harness the positive effects of SLPI.  
 Various groups have examined ways to protect SLPI function after in vivo 
administration to the lung. One group found that delivery of rSLPI in a liposomal carrier 
encapsulated and prevented SLPI degradation by respiratory proteases (75). While this 
formulation allowed for the modified SLPI to retain nearly 93% of its activity after 
challenge with serine proteases, the liquid preparation of encapsulated rSLPI was found 
to be unstable upon long-term storage and subsequent nebulization. To address this 
problem, liposomal rSLPI was prepared as a lyophilized dry powder and was micronized 
for inhaler use (394). This formulation process retained protection against proteolytic 
degradation, was storage stable, and was used for future animal studies (394).  When 
used in an asthma guinea pig model, encapsulated delivery of rSLPI improved stability, 
reduced clearance of SLPI in the lungs, and prevented inflammatory responses compared 
to control treated animals (343). In sum, this formulation could be used as a novel 
therapy for subpopulations with a protease/antiprotease imbalance such as smokers or 
patients with emphysema or COPD.  
Can we target other components of the respiratory antiprotease shield to protect against 
respiratory infection and/or chronic lung disease? 
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 Since SLPI has a short half-life, using more stable components of the antiprotease 
shield could serve as an attractive strategy to induce antiprotease levels to protect against 
respiratory infection and in the context of chronic lung disease. One class of antiproteases 
that could be used for therapeutic intervention involves the serpin family of antiproteases. 
Delivery of serpin into the lungs could prevent against the progression of chronic lung 
disease such as COPD and emphysema since point mutations of the serpin, alpha-1 
antitrypsin (α-1AT) results in an α-1AT deficiency and increases susceptibility to the 
development of chronic lung diseases (129-131, 395). In the late 1990s, Seersholm et al. 
performed a prospective, non-randomized trial in subjects with α-1AT deficiency and 
found that α-1AT infusions resulted in statistically slower decline in lung function 
compared to the control group (396). These findings were corroborated by other groups, 
indicating that α-1AT is a generally safe therapy that protects against lung decline (397, 
398).  
 However, the efficacy of α-1AT infusions depends on biweekly or monthly 
infusions, which can result in an average annual total health care cost ranging from 
$36,471 to $46,114 (399). As such, investigating strategies to locally deliver α-1AT 
could improve health care outcomes and health care costs. One method involves aerosol 
inhalation of α-1AT. Small, pilot studies have shown that α-1AT aerosolization 
significantly raises α-1AT above the protective threshold in the plasma and respiratory 
secretions and elevated anti-NE capacity (400). Additionally, aerosolized α-1AT has a 
half-life of 69.2 hours and is able to reach the lung periphery, indicating that this form of 
treatment could be used as a cost-effective mechanism to improve the antiprotease shield 
in susceptible populations (401).  
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 Moreover, inhaled serpin delivery could be used to block respiratory viral 
infection since serpins exhibit broad anti-viral properties (402-404).  Smee and 
colleagues revealed that a serpin, antithrombin III, blocks influenza A virus (IAV) H1N1 
replication in a 100-fold more potent manner than ribavirin, a ribonucleic analog used to 
inhibit viral replication (135). Moreover, this group reported that the inhibition of 
influenza strains had broad spectrum efficacies in in regards to H1N1, H3N2, H5N1, and 
influenza B. Others have shown that antithrombin III blocks opportunistic bacteria such 
as Streptococcus pneumoniae, which could be extremely important during secondary 
bacterial infections (405).  Furthermore, antithrombin III has an unusual long half-life, 
around 72 hours, in the lungs, suggesting that antithrombin III is highly stable in the 
lungs and could be used as an aerosolized therapeutic to prevent against respiratory 
infection. In sum, aerosolizing components of the antiprotease shield may serve as novel 
targets to lessen the development of chronic lung diseases and prevent respiratory 
microbial infections.  
6.3 Using sulforaphane (SFN) to induce SLPI expression and secretion: in vivo 
supplementation  
What is the in vivo bioavailability of SFN? 
 Our group has studied the impact of a nutritional antioxidant, SFN, on respiratory 
mucosal responses. We have shown that in vitro SFN supplementation, ranging from 1-
10 μM, modulates SLPI and transmembrane protease, serine 2 (TMPRSS2)  expression, 
blocks viral entry, and protects against IAV infection (Chapters 4 and 5) (249, 255).  
Furthermore, we have recently translated these findings in vivo, demonstrating that SFN 
treatment decreased markers of influenza replication in smokers in vivo (262). Others 
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have shown that supplementing alveolar macrophages from COPD patients with 10 μM 
SFN increased bacterial detection, enhanced phagocytosis, and elevated bacterial 
clearance (261). These reports demonstrate that SFN is a safe and cost-effective 
mechanism to boost respiratory host defense responses against microbial infection. 
However, since these mechanistic studies reported a specified SFN dose, it is imperative 
that in vivo SFN supplementation protocols are designed to deliver a similar range of 
dose to obtain the experimental results seen in vitro. 
 Our in vivo supplementation studies used a 200 gram dose of broccoli sprout 
homogenates (BSH) as the source for SFN (255, 262). To create the BSH, 111 grams of 
fresh sprouts, or about a 4 ounce package of commercially available Broccosprouts 
(Brassica Protection Products), was homogenized with water at a ratio of 1:1.2 (255, 
262). The BSH were made from single lots to insure uniform SFN content and were 
stored at -20ºC until used. Thawing had no effect on SFN content, as described in chapter 
4. Others have shown that a 200g dose of BSH contains approximately 102 μmol SFN, 
which would generate a peak SFN serum concentration of 1.02 μmol/l and induce 
respiratory antioxidant responses in vivo (254). This indicates that our studies treating in 
vitro nasal epithelial cell with 1-10 μmol/l SFN is within clinically relevant doses  (249, 
255).  
Can alternative SFN sources improve in vivo bioavailability?  
 Despite SFN serum concentrations ranging from 1-2 μmol/l, the half-life of this 
formulation is quite short, with a mean half-life of 1.77 hours (254). As such, 
investigating alternative dietary and pharmaceutical sources to increase the 
142 
 
bioavailability of SFN in vivo has been examined. In a cross-over study, Clarke et al. 
compared the in vivo bioavailability of SFN from human subjects consuming either 
broccoli sprouts or broccoli supplements in pill form (406). The authors found that the 
bioavailability of SFN was much lower when subjects consumed the broccoli pills 
compared to broccoli sprouts (406). Furthermore, the researchers determined that the 
peak serum concentration was significantly delayed in subjects consuming broccoli pills 
compared to broccoli sprouts (406). The authors speculated that these findings were 
dependent on the enzymatic isothiocyanate activation, which was devoid in the broccoli 
pills. As such, using broccoli pills are not appropriate strategies to attain high SFN 
plasma levels. Moreover, since broccoli pills are widely available (BroccoMax®, 
Vitacost Broccoli Sprout Extract), these findings have implications for consumers who 
assume that broccoli pills are equivalent to raw broccoli food ingestion.  
  Additionally, the use of “superbroccoli” could serve as an alternative strategy to 
increase plasma SFN levels. Found in the in the foothills of Italy, these wild broccoli 
plants contain 2-3 times the levels of glucoraphanin, a SFN precursor (407). Because of 
the clinical significance of identifying sources rich in SFN content, the wild broccoli 
hybrid, now named Benefortè®, is commercially available. Furthermore, clinical trials 
are ongoing to determine the impact of Benefortè® on prostate cancer development. 
Although the pharmacokinetics and bioavailability of SFN in Benefortè® remain 
unknown, the use of Benefortè® serves as a potential source to increase the 
bioavailability of SFN in vivo.  
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6.4 Alternative strategies to alter the protease/antiprotease balance: the use of 
complementary and alternative medicine (CAM) products  
 The use of CAM has gained increased interest to treat various diseases and 
disorders. CAM has been defined as “interventions neither taught widely in medical 
schools nor generally available in US hospitals” (408). CAM interventions can include 
acupuncture, homeopathy, hypnosis, and herbal products (409). The use of CAM is 
widespread in the US. A recent National Institute of Health’s National Center for 
Complementary and Alternative Medicine (NCCAM) report revealed that in the US, 38% 
of adults and 12% have used a form of CAM to treat symptoms associated with asthma, 
COPD, and rhinitis (410). However, in the US, herbal products are not regulated by the 
Food and Drug Administration, suggesting a need for investigative science to ascertain 
the safety and health implications of marketed herbal products. 
Could nuclear factor (erythroid-derived 2)- like 2 (Nrf2) activation be a common 
mechanism for CAM-induced host defense responses?  
 Proper functioning of Nrf2-dependent signaling is an important component of 
lung homeostasis and respiratory host defense. For example, influenza infection induces 
oxidative stress in the respiratory epithelium, which is controlled by the master regulator 
Nrf2 (411). Moreover, loss of Nrf2 signaling has been implicated in the development of 
chronic lung diseases (212, 214, 261, 412) . Additionally, we and others have shown that 
Nrf2 regulates components of the protease/antiprotease balance (Chapter 4) (214, 255). 
Since Nrf2 inhibits respiratory oxidative stress and protects against respiratory infection 
and chronic lung diseases, nutritional interventions that activate Nrf2 may be an attractive 
strategy to block oxidative stress, infection, and/or chronic lung disease. In addition to 
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SFN, there are many nutritional antioxidants, including curcumin and epigallcatechin-3-
gallate (EGCG), that induce Nrf2, modulate the protease/antiprotease balance, and 
protect against infection and/or chronic lung diseases (413).  
 Curcumin is a polyphenolic yellow pigment derived from turmeric that is popular 
as a spice and food coloring additive. Curcumin has been shown to possess anti-
inflammatory and antimicrobial properties. Specifically, curcumin inhibits NF-κB 
signaling by preventing IκB phosphorylation through IκB kinase (414). These findings 
were corroborated and expanded in epithelial cells exposed to cigarette smoke, indicating 
that curcumin blocks cigarette smoke induced NF-κB activation as well as oxidative 
stress markers such as cyclooxygenase-2 and MMP9 (415).  In the context of lung 
disease, curcumin decreases airway inflammation and immune infiltration in a mouse 
model of COPD (416). Furthermore, curcumin possesses broad anti-viral effects by 
inhibiting blocking human immunodeficiency virus (HIV) replication and HIV protein 
production (417). Additionally, Chen et al. revealed that curcumin treatment resulted in 
more than 90% reduction in viral replication by blocking hemagglutination activity (418). 
 Interestingly, curcumin has been shown to decrease proteases such as MMP3, 
MMP9, and TMPRSS2 (419, 420). Kundu et al. reported that curcumin dampened 
TMPRSS2 signaling by decreasing androgen receptor activation (420). We and others 
have shown that SFN decreases TMPRSS2 expression, which we speculate is mediating 
the SFN-dependent protection against influenza (Chapter 5) (259, 260). Together, these 
findings support the effect of nutritional Nrf2 inducers, such as curcumin and SFN, on 
TMPRSS2 expression and suggest that curcumin could protect against respiratory viruses 
that require TMPRSS2 for activation such as severe acute respiratory syndrome 
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coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), 
metapneumovirus, parainfluenza virus, and influenza virus (104, 105, 117, 171, 288-290, 
297). Since curcumin is tolerated and safe at high doses (12g/day), the use of curcumin 
could be widely used as a mechanism to block inflammatory cascades, lessen the 
development of chronic diseases, and protect against respiratory infection (421).   
 EGCG, a flavan-3-ol found mainly in green tea, is a potent Nrf2 inducer and is 
protective against airway inflammation and viral infection (244, 249, 422). Pretreatment 
of nasal fibroblasts and bronchial epithelial cells with EGCG blocks IL-8 production and 
release (423). Further studies have determined that EGCG blocks phosphorylation of p38 
protein involved in mitogen-activated protein kinase signaling (424). Similarly to 
curcumin, EGCG inhibits cigarette smoke -induced NF-κB activation and MMP9 
expression in human bronchial epithelial cells (425). In the context of lung diseases such 
as asthma, EGCG prevents MMP9 expression, inflammatory cell recruitment, and airway 
hyperresponsiveness after challenge in sensitized mice (426). These findings were 
supported by Qin et al. who revealed that EGCG suppressed recruitment of allergen 
specific T cells in mouse model of asthma (427). The authors determined that this 
mechanism was dependent on EGCG binding to pro-inflammatory cytokines, such as C-
X-C motif chemokines 9, 10, and 11, and inhibiting their chemotactic qualities. These 
findings show that EGCG, a component of a popular beverage, could decrease 
inflammation and lung disease.   
 In the context of an influenza infection, EGCG agglutinates influenza viruses and 
inhibits viral replication, which is dependent on influenza subtype (246, 247). Studies 
from Ling et al. demonstrated that oral administration of EGCG in mice infected with 
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influenza had nearly a 50% increase in survival rates, with nearly a 50% decrease in viral 
titers (248). Using in vitro human models, we have also shown that EGCG induces SLPI 
secretion, reduces TMPRSS2 secretion, and decreases influenza replication (171). In 
chapters 4 and 5, we paralleled these findings showing that SFN activated SLPI 
expression/secretion and decreased TMPRSS2 expression/secretion (255). Furthermore, 
we previously reported that EGCG blocked influenza entry into target epithelial cells, and 
in chapter 3, we demonstrated that SLPI prevents influenza entry (249).  One possible 
mechanism for the EGCG-mediated blocking of viral entry and replication is that EGCG 
induces SLPI and decreases TMPRSS2 to reduce viral activation, entry, and infection. 
Thus, supplementation with EGCG may be protective against influenza infection and 
other viruses that require proteolytic activation by TMPRSS2 such as SARS-CoV, 
MERS-CoV, metapneumovirus, parainfluenza virus, and influenza virus (104, 105, 117, 
171, 288-290, 297). In sum, CAM products could serve as a safe and affordable strategy 
to mitigate airway inflammation and lung disease. In addition, due to the emergence of 
anti-viral resistant pharmaceutical drugs, CAM products could be a potential therapy to 
avoid anti-viral resistance and protect against respiratory virus infection.  
6.5 The effects of inhaled oxidants on the protease/antiprotease balance: 
implications for chronic lung disease and respiratory infection  
 It has long been accepted that exposure to inhaled oxidants alters components of 
respiratory host defense, such as the protease/antiprotease balance. Modifying the 
protease/antiprotease balance can contribute to the development of lung diseases as well 
as increasing susceptibility to respiratory infection (71, 72, 215, 385) . We present data 
demonstrating that cigarette smoking alters the regulation and post-translational 
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modifications of SLPI (Chapter 2) (176). Further, we show that TMPRSS2 is elevated in 
the nasal secretions of smokers in vivo (Chapter 5). Our group and others have shown that 
cigarette smoking is a major susceptibility factor for increased respiratory viral infection 
(195-197, 199, 361). However, exposure to other inhaled environmental oxidants found 
in polluted air, such as biomass smoke and ozone, modifies components of the 
protease/antiprotease balance, exacerbates lung diseases, and increases susceptibility to 
respiratory infection. Further, if biomass smoke and/or ozone alter the 
protease/antiprotease balance, specific to SLPI and TMPRSS2, SFN could be an 
attractive therapy to lessen lung disease and viral infection in the context of these inhaled 
environmental oxidants and could expand the significance and impact of my findings 
(Chapters 4 and 5) (255).  
How does biomass and ozone affect respiratory health outcomes? 
 While tobacco smoke remains the main risk factor for lung cancer and chronic 
lung disease, biomass smoke contains similar components as cigarette smoke, including 
formaldehyde, benzene, and benzo(a)pyrene (428). Biomass smoke exposure is extremely 
common in developing countries and rural communities of developed countries since this 
option is a low-cost source for fuel, heating, lighting, and cooking (429). While the 
research investigating the mechanistic effects of biomass smoke on the respiratory 
mucosa is still in its infancy, groups have reported that biomass smoke causes alterations 
to respiratory host defense and leads to the development of chronic diseases in a similar 
manner to cigarette smoke exposure (430). Supporting these findings, Montano et al. 
reported that biomass smoke-induced COPD was mediated by inflammatory cell infiltrate 
and degradation of extracellular matrix components by MMPs (431). In the context of 
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respiratory infection, many groups have demonstrated that biomass exposure increases 
acute respiratory infections (432-434). While these reports are observational, we have 
preliminary data demonstrating that a component of biomass, wood smoke, decreases 
SLPI expression, which may be a potential mechanism for increased infections in these 
exposed populations (unpublished data).  As such, the use of SFN to induce SLPI 
expression and secretion may be a potential therapy for individuals chronically exposed 
to biomass.  
  Ozone is a one of the most abundant oxidants found in polluted air and induces 
oxidative stress on the respiratory epithelium. Inhalation of ozone recruits and activates 
inflammatory cells such as neutrophils, resulting in the release of pro-inflammatory 
mediators (435). In the context of lung diseases, ozone exacerbates asthma and COPD, 
increasing hospital admissions and aggravating symptoms (436, 437). In the context of 
the protease/antiprotease balance, others have reported that ozone exposure enhances 
respiratory protease activity, such as NE and MMPs, and decreases antiprotease function, 
such as α-1AT  and SLPI (438-442). Our group has confirmed these findings and showed 
that ozone decreased SLPI secretion and increased TMPRSS2 and other HA-activating 
proteases, which resulted in increased HA cleavage and influenza replication (171). Since 
we and others have shown that Nrf2 inducers such as SFN, curcumin, and EGCG alter 
SLPI and/or TMPRSS2 expression and secretion, the use of these CAM products would 
be applicable in the context of a biomass and/or ozone exposure to prevent against lung 
disease and respiratory infection.  
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6.6 Mitigating the effects of inhaled oxidants: policy and interventions  
 Since environmental oxidants such as cigarette smoke, biomass, and ozone 
negatively impact human health outcomes, there is a need for legislation and policy 
enforcement to lessen exposure. Starting in the early 1990s, smoking bans were adopted 
in the United States, and as of 2014, 28 states have passed statewide bans in enclosed 
public places such as restaurants and bars. The Center for Disease Control and others 
report that smoking bans reduce second hand smoke exposure, improve lung function 
among hospitality workers, and decrease rates of youth smoking (443-445). This type of 
policy action has affected companies such as CVS/pharmacy, who stopped selling all 
tobacco products in October of 2014. Despite having more than 7,600 stores nationwide 
and generating more than $1.5 billion dollars in annual revenue from the sale of tobacco 
products, CVS/pharmacy recognized the deleterious health effects caused by tobacco 
products and took steps to alleviate these outcomes (446). With the rising use of 
alternative tobacco products such as electronic cigarettes, little cigars, and hookahs, 
scientists must investigate the impact of these products and communicate with lawmakers 
to regulate and enact policy changes to protect the public health.   
 To reduce environmental oxidant exposure, such as ozone, the Air Quality Index 
(AQI) was developed by the US Environmental Protection Agency. The AQI is often 
printed in newspapers or reported in online weather websites to determine if the ambient 
ozone levels are safe. Additionally, the AQI describes ways to lessen the damaging 
effects of ozone. Studies have shown the use of AQI in schools leads to fewer asthma 
attacks, less visits to the school nurse, and decreased sick days (447). Reducing biomass 
exposure is another important public health concern since an estimated 3 billion people 
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burn biomass (448). Public health officials should advise those who are using biomass to 
cook outdoors, lessen the exposure to children, and switch to “cleaner” alternative fuel 
sources. If these options are unavailable, ensuring that there is proper ventilation in the 
enclosed spaces could be a possible strategy to mitigate biomass exposure. Additionally, 
the dissemination and use of biomass filters could be used to remove volatile compounds 
from the air and protect those exposed to the biomass combustion. As such, scientists and 
policy makers are tasked with the responsibility to inform, educate, and illicit change to 
promote positive public health projects.  
6.7 Conclusions and future directions  
 Secreted mediators from the respiratory epithelium such as proteins involved in 
the protease/antiprotease balance support respiratory homeostasis. Modifications to the 
delicate enzymatic balance can lead to the development of lung diseases such as 
emphysema or COPD Furthermore, altered protease/antiprotease balance, in favor for 
increased protease activity, is associated with increased respiratory viral infections. We 
demonstrated that smokers have altered intracellular regulation and extracellular 
modifications of a key respiratory antiprotease, SLPI (Chapter 2). Additionally, we 
revealed that SLPI is a novel biomarker that restricts influenza infection in vivo and in 
vitro (Chapter 3). Furthermore, we investigated the effect of nutritional antioxidants, such 
as SFN, on SLPI expression and found that SFN induced SLPI expression and secretion 
using in vivo and in vitro models (Chapter 4). Finally, we detailed that smokers have 
increased secretions of an influenza-activating protease, TMPRSS2 and that SFN 
supplementation decreased TMPRSS2 levels to protect against influenza infection in 
vitro (Chapter 5).  
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 Future short-term studies include investigating the mechanism underlying SFN-
mediated decrease of TMPRSS2 and protection against influenza infection in smokers. 
Furthermore, we are currently investigating the effects of inhaled oxidants, such as wood 
smoke, on SLPI and TMPRSS2 levels in the context of an IAV infection. We hypothesize 
that SFN supplementation may be a possible strategy to protect against wood smoke-
induced alterations to the protease/antiprotease balance and reduce susceptibility to IAV 
infection.  For long-term research projects, I would want to examine the effects of 
alternative Nrf2 inducers, such as curcumin and EGCG, on SLPI and TMPRSS2 
expression in the context of an influenza infection using the techniques I have developed. 
Lastly, I want to explore in our models if SLPI and TMPRSS2 are involved in other 
respiratory viruses that are sensitive to SLPI and/or TMPRSS2, such as parainfluenza 
virus, metapneumovirus, and the respiratory CoVs. In sum, this thesis investigated the 
effects of oxidants and antioxidants on the respiratory protease/antiprotease balance in 
the context of a respiratory viral infection. The findings presented in this document have 
broad implications for other inhaled oxidants, such as wood smoke and ozone, and 
identify possible nutritional therapeutic interventions to boost respiratory mucosal 
responses. These interventions could be used to delay the development of chronic lung 
diseases and/or protect against respiratory viral infection. 
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Baseline NLF from healthy smoking volunteers (n=11) was collected and analyzed for 
SLPI protein by ELISA. Urine from NLF from healthy smoking volunteers was collected 
and analyzed for cotinine/creatinine levels. SLPI levels and cotinine/creatinine levels 
were correlated and analyzed using linear regression analysis.  
Figure 6-1.  SLPI NLF levels from SM correlate with markers of cigarette smoking. 
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Baseline NLF from healthy smoking volunteers (n=11) was collected and analyzed for 
SLPI protein by ELISA. Following baseline NLF collection, volunteers underwent an 
LAIV inoculation protocol and serial NLF was collected 1-3 days post-LAIV inoculation 
and analyzed for HA mRNA expression by qRT-PCR. Baseline SLPI levels and HA 
mRNA AUC levels were correlated and analyzed using linear regression analysis 
  
Figure 6-2. SLPI NLF levels from SM do not correlate with markers of influenza 
replication. 
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